<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1812246448
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1989
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEPO-PROVERA VIAL I-M 150MG-ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEDROXYPROGESTERONE ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02AB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DEPO-PROVERA is a synthetic progestin (structurally related to the endogenous hormone progesterone) which has been demonstrated to possess several pharmacologic actions on the endocrine system:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibition of pituitary gonadotropins (FSH and LH);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of ACTH and hydrocortisone blood levels;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of circulating testosterone;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of circulating estrogen levels (as the result of both FSH inhibition and enzymatic induction of hepatic reductase, resulting in increased clearance of testosterone and consequent decreased conversion of androgens to estrogens).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All of these actions result in a number of pharmacological effects, as described below:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contraception</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of endometriosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of menopausal vasomotor symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic endometrial cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic renal cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depot-medroxyprogesterone acetate (DEPO PROVERA) injectable suspension is available in vials as 500 mg/3.3 mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is an <strong><em>Injectable</em></strong>: Suspension for intramuscular (IM) injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Depo-Provera </strong></p><ul><li>if you are allergic to medroxyprogesterone acetate or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Known or suspected pregnancy<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Undiagnosed vaginal bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe liver dysfunction<strong> </strong></p><ul><li>Known or suspected malignancy of the breast</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor , pharmacist or nurse before taking Depo-Provera</p><p>&nbsp;</p><p><em>General</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unexpected vaginal bleeding during therapy with Depo-Provera should be investigated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo-Provera may cause some degree of fluid retention, therefore, caution should be exercised in treating any patient with a pre-existing medical condition that might be adversely affected by fluid retention.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a history of treatment for clinical depression should be carefully monitored while receiving Depo-Provera therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients receiving Depo-Provera may exhibit a decreased glucose tolerance. Diabetic patients should be carefully observed while receiving such therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pathologist (laboratory) should be informed of the patient&rsquo;s use of Depo-Provera if endometrial or endocervical tissue is submitted for examination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The physician/laboratory should be informed that use of Depo-Provera may decrease the levels of the following endocrine biomarkers:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma/urinary steroids (e.g., cortisol, estrogen, pregnanediol, progesterone, testosterone)</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma/urinary gonadotrophins (e.g., luteinizing hormone (LH) and follicle-stimulating hormone (FSH)</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sex hormone-binding-globulin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medication should not be readministered, pending examination, if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilloedema or retinal vascular lesions, medication should not be readministered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo-Provera has not been causally associated with the induction of thrombotic or thromboembolic disorders , however, Depo-Provera is not recommended in any patient with a history of venous thromboembolism (VTE). Discontinuation of DEPO-PROVERA is recommended in patients who develop VTE while undergoing therapy with DEPO PROVERA.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; History of meningioma (a usually benign tumour that forms in the layers of tissue that cover your brain and spinal cord).</p><p><em>Additional Warnings and Precautions for Specific Use or Formulation</em></p><p><u>Contraception/Endometriosis - Injectable Formulations</u></p><p><u>Loss of Bone Mineral Density (BMD) </u></p><p>Use of DEPO-PROVERA injection reduces serum estrogen levels in premenopausal women and is associated with a statistically significant loss of BMD as bone metabolism accommodates to a lower estrogen level. Bone loss may be greater with increasing duration of use and may not be completely reversible in some women. It is unknown if use of DEPO-PROVERA injection during adolescence and early adulthood, a critical period of bone accretion, will reduce peak bone mass. In both adult <sup>&nbsp;</sup>and adolescent females , the decrease in BMD during treatment appears to be substantially reversible after DEPO-PROVERA injection is discontinued and ovarian estrogen production increases . After discontinuing Depo-Provera injection in adolescents, full recovery of mean BMD required 1 year at the lumbar spine, 4.6 years at the total hip and 3.4 years at the femoral neck .</p><p>In adults, BMD was observed for a period of 2 years after DEPO-PROVERA injection was discontinued and partial recovery of mean BMD towards baseline was observed at total hip, femoral neck and lumbar spine . A large observational study of female contraceptive users showed that use of Depo-Provera injection has no effect on a woman&rsquo;s risk for osteoporotic or non-osteoporotic fractures .</p><p><em>BMD Changes in Adult Women after Six Months of Treatment for Endometriosis </em></p><p>&nbsp;</p><p>Other birth control methods or endometrial treatments should be considered in the risk/benefit analysis for the use of DEPO-PROVERA injection in women with osteoporotic risk factors such as:&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic alcohol and/or tobacco use</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic use of drugs that can reduce bone mass, e.g., anticonvulsants or corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low body mass index (BMI) or eating disorder, e.g., anorexia nervosa or bulimia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic bone disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong family history of osteoporosis</p><p>It is recommended that all patients have adequate calcium and Vitamin D intake.</p><p><em>&nbsp;</em></p><p><em>Contraception </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most women using DEPO-PROVERA injectable suspension experience disruption of menstrual bleeding patterns (e.g., irregular or unpredictable bleeding/spotting, rarely, heavy or continuous bleeding). As women continue using DEPO-PROVERA injectable suspension, fewer experience irregular bleeding and more experience amenorrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term case-controlled surveillance of users of DEPO-PROVERA injectable suspension found slight or no increased overall risk of breast cancer and no overall increased risk of ovarian, liver, or cervical cancer and a prolonged, protective effect of reducing the risk of endometrial <strong>[</strong>cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEPO-PROVERA IM injectable suspension has a prolonged contraceptive effect. The median time to contraception following the last injection, for those who do conceive, is 10 months, with a range of 4 to 31 months, and is unrelated to the duration of use.</p><p>There was a tendency for women to gain weight while on therapy with DEPO PROVERA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If jaundice develops, consideration should be given to not readminister the drug.</p><p><u>&nbsp;</u></p><p><u>Sexually Transmitted Infections </u></p><p>Women should be counseled that DEPO-PROVERA injectable suspension does not protect against sexually transmitted infections (STIs) including HIV infection (AIDS) but equally, DEPO-PROVERA is a sterile injection and, used as directed, will not expose them to sexually transmitted infections. Safer sex practices including correct and consistent use of condoms reduce the transmission of STIs through sexual contact, including HIV.</p><p><u>Breast Cancer </u></p><p><em>&nbsp;</em></p><p><em>Gynecology</em></p><p><u>Treatment of Menopausal Vasomotor Symptoms/Opposition of Endometrial Effects of Estrogen in Menopausal Women Being Treated with Estrogen (Hormone Therapy)-All Formulations</u><u>:&nbsp; </u></p><p>Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of Hormone Therapy (HT) were not studied in the Women&rsquo;s Health Initiative (WHI) trial and, in the absence of comparable data, these risks should be assumed to be similar.</p><p><u>Breast Cancer </u></p><p>The use of combined oral estrogen/progestin by postmenopausal women has been reported to increase the risk of breast cancer. Results from a randomized placebo-controlled trial, the WHI trial, and epidemiological studies have reported an increased risk of breast cancer in women taking estrogen/progestin combinations for HT for several years. In the WHI conjugated equine estrogens (CEE) plus DEPO-PROVERA trial and observational studies, the excess risk increased with duration of use <strong>.</strong>The use of estrogen plus progestin has also been reported to result in an increase in abnormal mammograms requiring further evaluation.</p><p>In several epidemiologic studies no overall increased risk for breast cancer was found among users of injectable depot progestogens in comparison to non-users. However, an increased relative risk (e.g. 2.0 in one study) was found for women who currently used injectable depot progestogens or had used them only a few years before. It is not possible to infer from these data whether this increased rate of breast cancer diagnosis among current users is due to increased surveillance among current users, the biological effects of injectable progestogens, or a combination of reasons. <sup>&nbsp;</sup></p><p><u>Cardiovascular Disorders</u></p><p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. Several randomized, prospective trials on the long-term effects of a combined estrogen/progestin regimen in postmenopausal women have reported an increased risk of cardiovascular events such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coronary Artery Disease</p><p>There is no evidence from randomized controlled trials of cardiovascular benefit with continuous combined conjugated estrogen and medroxyprogesterone acetate (DEPO PROVERA). Two large clinical trials [WHI CEE/DEPO-PROVERA and Heart and Estrogen/progestin Replacement Study (HERS) showed a possible increased risk of cardiovascular morbidity in the first year of use and no overall benefit.<sup> </sup></p><p>In the WHI CEE/DEPO-PROVERA trial, an increased risk of coronary heart disease (CHD) events (defined as nonfatal myocardial infarction and CHD death) was observed in women receiving CEE/DEPO-PROVERA compared to women receiving placebo (37 vs. 30 per 10,000 person years). The increase in VTE risk was observed in year one and persisted over the observation period</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke</p><p>In the WHI CEE/DEPO-PROVERA trial, an increased risk of stroke was observed in women receiving CEE/DEPO-PROVERA compared to women receiving placebo (29 vs. 21 per 10,000 person-years). The increase in risk was observed in year one and persisted over the observation period</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolism / Pulmonary embolism</p><p>HT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e., deep vein thrombosis or pulmonary embolism. In the WHI CEE/DEPO-PROVERA trial, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism was observed in women receiving CEE/DEPO-PROVERA compared to women receiving placebo.&nbsp; The increase in risk was observed in year one and persisted over the observation period.</p><p><u>Dementia</u></p><p>The Women&rsquo;s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, CEE/DEPO-PROVERA reported an increased risk of probable dementia in postmenopausal women 65 years of age or older. In addition, CEE/DEPO-PROVERA therapy did not prevent mild cognitive impairment (MCI) in these women. Use of hormone therapy (HT) to prevent dementia or MCI in women 65 years or older is not recommended.</p><p><u>Ovarian Cancer</u></p><p>Current use of estrogen only or estrogen plus progestin products in post-menopausal women for five or more years, has been associated with an increased risk of ovarian cancer in some epidemiological studies. Past users of estrogen only or estrogen plus progestin products were at no increased risk for ovarian cancer. Other studies did not show a significant association. The WHI CEE/DEPO-PROVERA trial reported that estrogen plus progestin increased the risk of ovarian cancer, but this risk was not statistically significant. In one study, women who use HRT are at increased risk of fatal ovarian cancer.</p><p><u>History and Physical Exam Recommendation</u></p><p>A complete medical and family history should be taken before the initiation of any hormone therapy. Pretreatment and periodic physical examinations should include special reference to blood pressure, breasts, abdomen, and pelvic organs, including cervical cytology.</p><p><em>&nbsp;</em></p><p><em>Gynecology-Injectable Formulations</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged anovulation with amenorrhoea and/or erratic menstrual patterns may follow the administration of either a single or multiple injectable dose of DEPO PROVERA.</p><p><em>&nbsp;</em></p><p><em>Oncology</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEPO-PROVERA may produce Cushingoid symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients receiving DEPO-PROVERA may exhibit suppressed adrenal function. DEPO-PROVERA may decrease ACTH and hydrocortisone blood levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The physician/laboratory should be informed that in addition to the endocrine biomarkers , the use of DEPO-PROVERA in oncology indications may also cause partial adrenal insufficiency (decrease in pituitary-adrenal axis response) during metyrapone testing. Thus the ability of adrenal cortex to respond to ACTH should be demonstrated before metyrapone is administered.</p><p><em>&nbsp;</em></p><p><em>Oncology-Injectable Formulations</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged anovulation with amenorrhoea and/or erratic menstrual patterns may follow the administration of either a single or multiple injectable dose of DEPO PROVERA.</p><p><em>&nbsp;</em></p><p><em>Oral Formulations and High Dose Parenteral Formulations (e.g., oncology use in pre-menopausal women) </em></p><p><u>Decrease in Bone Mineral Density</u></p><p>There are no studies on the bone mineral density (BMD) effects of orally administered DEPO-PROVERA or the high doses of parenteral DEPO-PROVERA (e.g., for oncology use). An evaluation of BMD may be appropriate in some patients who use DEPO-PROVERA long-term , (<strong>see above &ndash; Loss of Bone Mineral Density</strong>).&nbsp;</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Depo-Provera IM is not indicated before menarche. Data are available in adolescent females (12‑18&nbsp;years). The safety and effectiveness of Depo-Provera IM are expected to be the same for postmenarcheal adolescent and adult females</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and&nbsp; Depo Provera</strong></p><p>Tell your doctor or pharmacist&nbsp; if you aretaking , have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Medroxyprogesterone acetate (DEPO PROVERA) is metabolized in-vitro primarily by hydroxylation via the CYP3A4. Specific drug-drug interaction studies evaluating the clinical effects with CYP3A4 inducers or inhibitors on DEPO-PROVERA have not been conducted and therefore the clinical effects of CYP3A4 inducers or inhibitors are unknown.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Pregnancy</p><p>DEPO-PROVERA is contraindicated in women who are pregnant.&nbsp;</p><p>Some reports suggest under certain circumstances, an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in fetuses.</p><p>Infants from unintentional pregnancies that occur 1 to 2 months after injection of DEPO-PROVERA injectable suspension may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal death. The attributable risk is low because pregnancies while on DEPO-PROVERA are uncommon.&nbsp; There is no definitive information for the other formulations of DEPO-PROVERA .</p><p>If the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus.</p><p><em>&nbsp;</em></p><p>Lactation</p><p>DEPO-PROVERA and its metabolites are excreted in breast milk. There is no evidence to suggest that this presents any hazard to the nursing child <strong>.</strong></p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>The effect of medroxyprogesterone acetate on the ability to drive and use machinery has not been systematically evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Injectable suspensions should be shaken well before use.</p><p><em>&nbsp;</em></p><p><em>Contraception</em></p><p>Depo-Provera intramuscular (IM) injectable suspensions should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.<strong><em>&nbsp; </em></strong></p><p><u>&nbsp;</u></p><p><u>Intramuscular (IM) </u></p><p>The recommended dose is 150 mg of&nbsp; Depo-Provera injectable suspension every 3 months (12‑13&nbsp;weeks) administered by intramuscular injection in the gluteal or deltoid muscle.&nbsp; The IM suspension is not formulated for subcutaneous injection.<sup>&nbsp; </sup></p><p>&nbsp;</p><p><em>First injection </em></p><p>The initial IM injection should be given during the first 5 days after the onset of a normal menstrual period; within 5&nbsp;days postpartum if not breast-feeding; or, if exclusively breast-feeding, at or after 6 weeks postpartum.</p><p><em>Second and subsequent injections</em></p><p>If the time interval between IM injections is greater than 13 weeks, pregnancy should be ruled out before administering the next IM injection.</p><p><em>Switching from other methods of contraception </em></p><p>When switching from other contraceptive methods, (Depo-Provera IM) should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods (e.g., patients switching from oral contraceptives should have their first injection of Depo-Provera within 7 days after taking their last active pill).</p><p><em>&nbsp;</em></p><p><em>Gynecology</em></p><p>Use of combined estrogen/progestin therapy in postmenopausal women should be limited to the lowest effective dose <strong>&nbsp;</strong>and shortest duration consistent with treatment goals and risks for the individual woman, and should be periodically evaluated.</p><p>Periodic check-ups are recommended with a frequency and nature adapted to the individual woman.</p><p>Unless there is a previous diagnosis of endometriosis, it is not recommended to add a progestin in a woman without an intact uterus.</p><p><u>&nbsp;</u></p><p><u>Endometriosis</u><u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo-Provera , given intramuscularly 50 mg weekly or 100 mg every 2 weeks for at least 6 months.</p><p><u>Menopausal Vasomotor Symptoms</u><u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo-Provera given intramuscularly 150 mg every 12 weeks.</p><p><em>&nbsp;</em></p><p><em>Oncology</em></p><p><u>Recurrent and/or Metastatic Breast Cancer</u><em> </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo-Provera initial dose 500 to 1000 mg intramuscularly per day for 28 days. The patient should then be placed on a maintenance schedule of 500 mg twice weekly as long as she responds to treatment.</p><p><u>Recurrent and/or Metastatic Endometrial or Renal Cancer</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo-Provera 400 to 1000 mg intramuscularly per week is recommended initially. If improvement is noted within a few weeks or months and the disease appears stabilized, it may be possible to maintain improvement with as little as 400 mg per month.</p><p><u>Hepatic Insufficiency</u></p><p>No clinical studies have evaluated the effect of hepatic disease on the pharmacokinetics of Depo Provera. However, Depo-Provera is almost exclusively eliminated by hepatic metabolism and steroid hormones may be poorly metabolized in patients with severe liver insufficiency .</p><p><u>Renal Insufficiency</u></p><p>No clinical studies have evaluated the effect of renal disease on the pharmacokinetics of Depo Provera. However, since Depo-Provera is almost exclusively eliminated by hepatic metabolism, no dosage adjustment should be necessary in women with renal insufficiency</p><p>&nbsp;</p><p><strong>Use in Children and adolescents</strong></p><p>Depo-Provera IM is not indicated before menarche. Data are available in adolescent females (12‑18&nbsp;years). The safety and effectiveness of Depo-Provera IM are expected to be the same for postmenarcheal adolescent and adult females</p><p><em>&nbsp;</em></p><p><strong>If you forget to&nbsp; take Depo Provera</strong></p><p>If the time interval between IM injections is greater than 13 weeks, pregnancy should be ruled out before administering the next IM injection.</p><p>&nbsp;</p><p><strong>If you stop taking Depo Provera</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor , pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp; Weight gain</p><p>&middot;&nbsp;&nbsp; Weight loss</p><p>&middot;&nbsp;&nbsp; Headaches</p><p>&middot;&nbsp;&nbsp; Nervousness</p><p>&middot;&nbsp;&nbsp; Stomach ache</p><p>&middot;&nbsp;&nbsp; Stomach complaints</p><p>&nbsp;</p><p><strong>Common</strong> (may affect 1 to 10 people in 100):</p><p>&middot;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp; Reduced libido</p><p>&middot;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp; Bloated feeling</p><p>&middot;&nbsp;&nbsp; Skin rashes</p><p>&middot;&nbsp;&nbsp; Acne</p><p>&middot;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp; Increased vaginal discharge (white discharge)</p><p>&middot;&nbsp;&nbsp; Feeling of tension in the breasts</p><p>&middot;&nbsp;&nbsp; Backache</p><p>&middot;&nbsp;&nbsp; Water retention</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect 1 to 10 people in 1,000):</p><p>&middot;&nbsp;&nbsp; Allergic reaction to medicine</p><p>&middot;&nbsp;&nbsp; Insomnia</p><p>&middot;&nbsp;&nbsp; Drowsiness</p><p>&middot;&nbsp;&nbsp; Cramps</p><p>&middot;&nbsp;&nbsp; Hot flushes</p><p>&middot;&nbsp;&nbsp; Impaired liver function</p><p>&middot;&nbsp;&nbsp; Hives</p><p>&middot;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp; Excessive body hair</p><p>&middot;&nbsp;&nbsp; Vaginal bleeding outside the menstrual cycle: irregular, unpredictable, increased or reduced bleeding</p><p>&middot;&nbsp;&nbsp; Pelvic pain</p><p>&middot;&nbsp;&nbsp; Lactation</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp; Thromboembolic disorders (diseases in which the blood vessels are obstructed by blood clots)</p><p>&middot;&nbsp;&nbsp; Thrombophlebitis (inflammation of a vein with a blood clot)</p><p>&middot;&nbsp;&nbsp; Jaundice</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Pain/sensitivity at the injection site</p><p>&nbsp;</p><p><strong>Not known</strong> (cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp; Pain in the breasts</p><p>&middot;&nbsp;&nbsp; Severe allergic reactions with potentially fatal outcome (anaphylaxis)</p><p>&middot;&nbsp;&nbsp; Angio-oedema</p><p>&middot;&nbsp;&nbsp; Prolonged absence of ovulation</p><p>&middot;&nbsp;&nbsp; Absence of orgasm</p><p>&middot;&nbsp;&nbsp; Acquired lipodystrophy</p><p>&middot;&nbsp;&nbsp; Joint cramps</p><p>&middot;&nbsp;&nbsp; Muscle spasms</p><p>&middot;&nbsp;&nbsp; Vaginal inflammation</p><p>&middot;&nbsp;&nbsp; Absence of menstrual bleeding</p><p>&middot;&nbsp;&nbsp; Fatigue</p><p>&middot;&nbsp;&nbsp; Reaction at the injection site</p><p>&middot;&nbsp;&nbsp; Persistent tissue loss/depression/dimple at the injection site</p><p>&middot;&nbsp;&nbsp; Nodes/swelling at the injection site</p><p>&middot;&nbsp;&nbsp; Reduced tolerance to sugar (glucose)</p><p>&middot;&nbsp;&nbsp; Loss of bone mineral density</p><p>&middot;&nbsp;&nbsp; Moon face (round, red, swollen face)</p><p>&middot;&nbsp;&nbsp; Pulmonary embolism (disease in which the blood vessels of the lungs are obstructed by blood clots)</p><p>&middot;&nbsp;&nbsp; Osteoporosis (reduction of bone mass)</p><p>&middot;&nbsp;&nbsp; Osteoporotic fractures related to osteoporosis</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Reporting side effects: </strong></p><p>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To Report side effects:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>Do not refrigerate or freeze.</p><p>Store vial upright.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label,&nbsp; carton - The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life 48 months.</p><p>&nbsp;</p><p>Do not use this medicine if you notice {description of the visible signs of deterioration}.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance(s) is: Medroxyprogesterone acetate</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient(s) are: Macrogol 3350, polysorbate 80, sodium chloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, water for injections, hydrochloric acid and/or sodium hydroxide for the pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sterile aqueous suspension for intramuscular injection.
Presentations:
DEPO-PROVERA 150 mg suspension for injection:
-	3.3 ml vial
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer S.A., 17 Boulevard de la Plaine, 1050&nbsp;Brussels, Belgium.</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ديبو بروفيرا هو بروجستين اصطناعي (ذو تركيب بنائي قريب من هرمون البروجستيرون الداخلي الباطني) الذي ثبت أن له عدة تأثيرات دوائية على جهاز الغدد الصماء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط إفراز هرمونات موجهات الغدد التناسلية الخاصة بالغدة النخامية (الهرمون المنشط للبصيلة (FSH) والهرمون الملوتن (LH))؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقليل مستويات الهرمون الموجه لقشر الكظر (ACTH) والهيدروكورتيزون في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقليل نسبة التيستوستيرون الدائر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقليل مستويات الإستروجين الدائر (كنتيجة لتثبيط كل من الهرمون المنشط للبصيلة والحث الإنزيمي للمختزل الكبدي، مما ينتج عنه زيادة في تصفية التيستوستيرون ويترتب عليه انخفاض في معدل تحويل الأندروجينات إلى إستروجينات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وينتج عن جميع هذه التأثيرات مجموعة من الآثار الدوائية، كما هو موضح أدناه:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>منع الحمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج انتباذ بطانة الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الأعراض الوعائية الحركية المصاحبة لانقطاع الحيض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي المتكرر و/أو النقيلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان بطانة الرحم المتكرر و/أو النقيلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الكلى المتكرر و/أو النقيلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معلق أسيتات ميدروكسي بروجستيرون الادخاري (ديبو بروفيرا) القابل للحقن متاح في قوارير ذات تركيز&nbsp; ٥٠٠ ملجم/٣٫٣ مل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهو معلق <strong><em>قابل للحقن</em></strong>: عن طريق العضل (IM).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال&nbsp; ديبو بروفيرا</strong></p><ul><li dir="RTL">إذا كنتِ مصابة بالحساسية تجاه أسيتات ميدروكسي بروجستيرون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود حمل أو الاشتباه في وجوده<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود نزيف مهبلي لم يتم تشخيصه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بخلل وظيفي شديد في الكبد<strong> </strong></p><ul><li dir="RTL">الإصابة بورم خبيث في الثدي أو الاشتباه في وجوده</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ديبو بروفيرا</strong></p><p dir="RTL">تحدثي مع طبيبكِ أو الصيدلي أو الممرضة قبل استخدام ديبو بروفيرا</p><p dir="RTL">&nbsp;</p><p><strong><em>تحذيرات عامة</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي الخضوع للفحص في حالة الإصابة بنزيف مهبلي غير متوقع أثناء العلاج باستخدام ديبو بروفيرا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يتسبب ديبو بروفيرا في حدوث احتباس للسوائل بدرجة ما، ولذلك، ينبغي توخي الحذر عند علاج أي مريضة تعاني من حالة طبية موجودة من قبل يمكن أن تتأثر سلبًا باحتباس السوائل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المريضات اللاتي لديهن تاريخ من العلاج من الاكتئاب الإكلينيكي، ينبغي مراقبتهن عن قرب أثناء تلقيهن العلاج باستخدام ديبو بروفيرا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تنخفض القدرة على تحمل الجلوكوز لدى بعض المريضات اللاتي يتلقين ديبو بروفيرا. وينبغي مراقبة المريضات اللاتي يعانين من داء السكري عن قرب أثناء تلقيهن هذا العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي إخطار متخصص علم الأمراض (المعمل) عن استخدام المريضة لديبو بروفيرا إذا تم إرسال نسيج بطانة الرحم أو عنق الرحم لفحصه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي إخبار الطبيب/المعمل بأن استخدام ديبو بروفيرا يمكن أن يقلل من مستويات المؤشرات الحيوية التالية للغدد الصماء:</p><p dir="RTL">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات في البلازما/البول (مثل الكورتيزول، الإستروجين، البريجنانديول، البروجستيرون، التيستوستيرون)</p><p dir="RTL">&zwnj;ب.&nbsp;&nbsp;&nbsp; موجهات الغدد التناسلية في البلازما/البول (مثل الهرمون الملوتن والهرمون المنشط للبصيلة)</p><p dir="RTL">&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp; الجلوبيولين المرتبط بالهرمون الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ألا تتم إعادة إعطاء الدواء أو تعليق الفحص، إذا حدث فقدان مفاجئ جزئي أو كلي للرؤية أو في حالة البدء المفاجئ لجحوظ العينين أو ازدواج الرؤية أو الصداع النصفي. إذا أظهر الفحص وجود تورم في الحليمة أو آفات وعائية شبكية، ينبغي ألا تتم إعادة إعطاء الدواء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا يرتبط استخدام ديبو بروفيرا سببيًا بتحفيز الاضطرابات الخثارية أو الانصمامية الخثارية، ومع ذلك، لا يوصى باستخدام ديبو بروفيرا مع أي مريضة لها تاريخ من الإصابة بالانصمام الخثاري الوريدي (VTE). ويوصى بإيقاف العلاج في حالة المريضات اللاتي يصبن بالانصمام الخثاري الوريدي أثناء خضوعهن للعلاج باستخدام ديبو بروفيرا.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تاريخ من الإصابة بالورم السحائي (ورم حميد عادة يتشكل في طبقات الأنسجة التي تغطي الدماغ والحبل الشوكي).&nbsp;</p><p><strong><em>تحذيرات واحتياطات إضافية للاستخدام الخاص أو التركيبات</em></strong></p><p><u>منع الحمل/انتباذ بطانة الرحم - التركيبات القابلة للحقن</u></p><p dir="RTL"><u>فقدان الكثافة المعدنية للعظم </u></p><p dir="RTL">يقلل استخدام حقن ديبو بروفيرا من مستويات الإستروجين في مصل الدم لدى السيدات في المرحلة السابقة لانقطاع الحيض ويرتبط بفقدان ذي دلالة إحصائية للكثافة المعدنية للعظم نظرًا لأن أيض العظم يتكيف مع مستوى الإستروجين المنخفض. يمكن أن يُفقد العظم بشكل أكبر مع زيادة مدة الاستخدام ويمكن أن يكون غير قابل للعكس بالكامل لدى بعض السيدات. من غير المعروف إذا ما كان استخدام حقن ديبو بروفيرا أثناء مرحلة المراهقة وفي بداية مرحلة البلوغ، وهي فترة حيوية لنمو العظم، سيخفض من ذروة الكتلة العظمية أم لا. وبدا أن انخفاض الكثافة المعدنية للعظم في كل من البالغات والمراهقات أثناء العلاج يكون قابلًا للعكس إلى حد كبير بعد إيقاف استخدام حقن ديبو بروفيرا وزيادة إنتاج الإستروجينات المبيضية. بعد إيقاف العلاج باستخدام حقن ديبو-بروفيرا في المراهقات، تطلب التعافي التام من متوسط انخفاض الكثافة المعدنية للعظم في الفقرات القطنية سنة واحدة وفي كامل عظمة الفخذ ٤٫٦ سنوات وفي عنق الفخذ ٣٫٤سنوات.</p><p dir="RTL">في البالغات، تمت مراقبة الكثافة المعدنية للعظم خلال فترة تبلغ سنتين بعد إيقاف استخدام حقن ديبو بروفيرا ولوحظ التعافي الجزئي من متوسط انخفاض الكثافة المعدنية للعظم بمعدل يقترب من الخط القاعدي، وهذا في كامل عظمة الفخذ وفي عنق الفخذ وفي الفقرات القطنية. وأوضحت دراسة رصدية كبرى أجريت على السيدات اللاتي يستخدمن وسائل منع الحمل أن استخدام حقن ديبو-بروفيرا ليس له أثر على خطر إصابة السيدات بالكسور الناتجة عن هشاشة العظم أو غير الناتجة عن ذلك.</p><p dir="RTL"><em>تغيرات في الكثافة المعدنية للعظم في السيدات البالغات بعد العلاج لمدة ٦ أشهر من انتباذ بطانة الرحم </em></p><p dir="RTL">ينبغي وضع وسائل منع الحمل أو علاجات بطانة الرحم الأخرى في الاعتبار عند تحليل مخاطر/فوائد استخدام حقن ديبو بروفيرا في السيدات اللاتي لديهن عوامل خطورة للإصابة بهشاشة العظم، مثل:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستخدام المزمن للكحول و/أو التبغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستخدام المزمن للعقاقير التي قد تؤدي إلى انخفاض الكتلة العظمية، مثل مضادات التشنجات أو الستيرويدات القشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مؤشر كتلة الجسم (BMI) أو اضطرابات الطعام، مثل القهم العصبي أو النهم العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض العظم الأيضي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التاريخ العائلي الذي يشير بقوة إلى الإصابة بهشاشة العظام</p><p dir="RTL">يوصى بأن تتناول جميع المريضات كمية كافية من الكالسيوم وفيتامين د.</p><p><em>منع الحمل </em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معظم السيدات اللاتي يستخدمن معلق ديبو بروفيرا القابل للحقن يعانين من خلل في أنماط النزيف الحيضي (مثل نزيف/بقع من الدم بشكل غير منتظم أو غير متوقع، نزيف نادر أو غزير أو مستمر). ومع استمرار استخدام السيدات لمعلق ديبو بروفيرا القابل للحقن، يعاني القليل منهن من النزيف غير المنتظم ونسبة أكبر تعاني من توقف الحيض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وُجد من خلال الرقابة طويلة الأمد للحالات المُراقبة من السيدات اللاتي يستخدمن معلق ديبو بروفيرا القابل للحقن، أن هناك زيادة طفيفة أو لا توجد زيادة في إجمالي مخاطر الإصابة بسرطان الثدي ولا توجد زيادة في إجمالي مخاطر الإصابة بسرطان المبيض أو الكبد أو سرطان عنق الرحم وأنه يوجد أثر وقائي مطول لخفض معدل الإصابة بسرطان بطانة الرحم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدى ديبو بروفيرا القابل للحقن في العضل أثر مطول مانع للحمل. الفترة الوسيطة لمنع الحمل بعد آخر حقنة، بالنسبة لأولئك القادرات على الحمل، هي ١٠ شهور، مع مدى يتراوح بين ٤ و٣١ شهرًا، وهو غير مرتبط بمدة الاستخدام.</p><p dir="RTL">وكان هناك ميل لدى النساء لاكتساب الوزن أثناء العلاج باستخدام ديبو بروفيرا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تطور الأمر للإصابة باليرقان، ينبغي وضع عدم إعادة إعطاء العقار في الاعتبار.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>العدوى المنتقلة جنسيًا </u></p><p dir="RTL">ينبغي تنبيه المريضات بأن معلق ديبو بروفيرا القابل للحقن لا يحمي من الإصابة بالعدوى المنتقلة جنسيًا (STI) بما في ذلك عدوى فيروس نقص المناعة البشرية (الإيدز) ولكن بنفس القدر، فإن ديبو بروفيرا هي حقن معقمة، ولن تعرضهن، عند استخدامها وفقًا للتعليمات، للإصابة بالعدوى المنتقلة جنسيًا. إن ممارسة الجنس بشكل آمن، بما في ذلك، الاستخدام المتسق والصحيح للأوقية الذكرية، تخفض من معدل انتقال العدوى المنتقلة جنسيًا من خلال التواصل الجنسي، بما في ذلك، فيروس نقص المناعة البشرية.</p><p dir="RTL"><u>سرطان الثدي </u></p><p><em>&nbsp;</em></p><p><em>طب أمراض النساء</em></p><p dir="RTL"><u>علاج الأعراض الوعائية الحركية المصاحبة لانقطاع الحيض/مقاومة آثار الإستروجين على بطانة الرحم لدى السيدات في مرحلة انقطاع الحيض اللاتي يتم علاجهن باستخدام الإستروجين (العلاج الهرموني)-جميع التركيبات:&nbsp; </u></p><p dir="RTL">لم تتم دراسة الجرعات الأخرى للإستروجينات المقترنة التي تؤخذ عبر الفم عند استخدامها بالتزامن مع أسيتات ميدروكسي بروجستيرون، والمركبات وأشكال الجرعات الأخرى من العلاج الهرموني (HT) في تجربة مبادرة صحة المرأة WHI))، وفي ظل غياب البيانات القابلة للمقارنة، ينبغي افتراض أن هذه المخاطر متشابهة.</p><p dir="RTL"><u>سرطان الثدي </u></p><p dir="RTL">تم الإبلاغ عن أن استخدام علاج الإستروجين/البروجستين المركب الذي يؤخذ عبر الفم بواسطة السيدات في المرحلة التالية لانقطاع الطمث يزيد من خطورة الإصابة بسرطان الثدي. وقد أفادت النتائج التي تم الحصول عليها من تجربة عشوائية مُراقبة بدواء وهمي، وهي تجربة مبادرة صحة المرأة، والدراسات الوبائية بأنه توجد زيادة في خطر الإصابة بسرطان الثدي في السيدات اللاتي يستخدمن علاج الإستروجين/البروجستين المركب ضمن خضوعهن للعلاج الهرموني لعدة سنوات. وفي التجربة والدراسات الرصدية التي أجرتها مبادرة صحة المرأة على استخدام الإستروجينات المقترنة الخيلية (CEE) مع ديبو بروفيرا، ارتفعت نسبة الخطر الزائد مع زيادة مدة الاستخدام. وتم أيضًا الإبلاغ عن أن استخدام الإستروجين مع البروجستين نتج عنه زيادة في صور الثدي الشعاعية غير الطبيعية الأمر الذي تتطلب تقييمًا إضافيًا.</p><p dir="RTL">في العديد من الدراسات الوبائية، لم تُلاحظ زيادة بشكل عام في خطر الإصابة بسرطان الثدي بين السيدات اللاتي يستخدمن البروجيستوجينات الادخارية القابلة للحقن بالمقارنة مع السيدات اللاتي لا يستخدمنه. ومع ذلك، لوحظت زيادة في الخطر النسبي (على سبيل المثال، ٢٫٠ في دراسة واحدة) في السيدات اللاتي يستخدمن البروجيستوجينات الادخارية القابلة للحقن حاليًا أو اللاتي استخدمنها بضع سنوات فقط قبل ذلك. ليس من الممكن أن نستنتج من هذه البيانات إذا ما كان هذا المعدل المرتفع لتشخيص الإصابة بسرطان الثدي بين المستخدمات الحاليات هو نتيجة زيادة الرقابة على المستخدمات الحاليات أم نتيجة الآثار الحيوية للبروجيستوجينات القابلة للحقن أم هو نتاج مجموعة من الأسباب. <sup>&nbsp;</sup></p><p dir="RTL"><u>الاضطرابات القلبية الوعائية</u></p><p dir="RTL">ينبغي ألا يتم استخدام الإستروجينات لمنع الإصابة بالأمراض القلبية الوعائية، سواء تم استخدامها مع البروجستينات أو بدونها. أفادت العديد من التجارب الاستباقية العشوائية التي أجريت على السيدات في المرحلة التالية لانقطاع الطمث لمعرفة الآثار طويلة الأمد للعلاج وفقًا للنظام الذي يتضمن استخدام علاج الإستروجين/البروجستين المركب، بأن هناك زيادة في خطر الإصابة بأحداث قلبية وعائية مثل احتشاء عضلة القلب وأمراض القلب التاجية والسكتة الدماغية والانصمام الخثاري الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الشريان التاجي</p><p dir="RTL">لا يوجد دليل من خلال التجارب العشوائية المُراقبة على الفوائد القلبية الوعائية التي تنتج عن الاستخدام المستمر لعلاج مركب من الإستروجين المقترن وأسيتات ميدروكسي بروجستيرون (ديبو بروفيرا). أظهرت التجربتان الإكلينيكيتان الكبيرتان [التجربة التي أجرتها مبادرة صحة المرأة على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا (WHI CEE/DEPO PROVERA) والدراسة التي تُدعى القلب والاستخدام البديل للإستروجين/البروجستين (HERS) أنه من الممكن أن ترتفع نسبة انتشار الأمراض القلبية الوعائية خلال أول سنة من الاستخدام وأنه لا توجد فائدة بشكل عام.<sup> </sup></p><p dir="RTL">في التجربة التي أجرتها مبادرة صحة المرأة على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا، لوحظت زيادة في خطر الإصابة بأحداث مرض القلب التاجي (CHD) (تُعرف على أنها احتشاء عضلة القلب غير المميت والموت بمرض القلب التاجي) في السيدات اللاتي يتلقين العلاج باستخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا مقارنةً بالسيدات اللاتي يتلقين الدواء الوهمي (٣٧ مقابل ٣٠ لكل ١٠٠٠٠ سيدة في السنة المُحددة وفقًا للأشخاص المعرضين). ولوحظت زيادة في خطر الإصابة بالانصمام الخثاري الوريدي في السنة الأولى واستمر الخطر طوال فترة الملاحظة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية</p><p dir="RTL">في التجربة التي أجرتها مبادرة صحة المرأة على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا، لوحظت زيادة في خطر الإصابة بالسكتة الدماغية في السيدات اللاتي يتلقين العلاج باستخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا مقارنةً بالسيدات اللاتي يتلقين الدواء الوهمي (٢٩ مقابل ٢١ لكل ١٠٠٠٠ سيدة في السنة المُحددة وفقًا للأشخاص المعرضين). لوحظت زيادة في خطر الإصابة في السنة الأولى واستمر الخطر طوال فترة الملاحظة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانصمام الخثاري الوريدي/الانصمام الرئوي</p><p dir="RTL">يرتبط العلاج الهرموني بارتفاع الخطر النسبي للإصابة بالانصمام الخثاري الوريدي، أي الخثار الوريدي العميق، أو الانصمام الرئوي. في التجربة التي أجرتها مبادرة صحة المرأة على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا، لوحظ ارتفاع معدل الإصابة بالانصمام الخثاري الوريدي للضعفين، بما في ذلك الخثار الوريدي العميق والانصمام الرئوي في السيدات اللاتي يتلقين العلاج باستخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا مقارنةً بالسيدات اللاتي يتلقين الدواء الوهمي.&nbsp; لوحظت زيادة خطر الإصابة في السنة الأولى واستمر الخطر طوال فترة الملاحظة.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الخرف</u></p><p dir="RTL">أبلغت الدراسة التي أجرتها مبادرة صحة المرأة على الذاكرة (WHIMS)، وهي دراسة مساعدة للدراسة التي أجرتها المبادرة على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا، نسبة متزايدة من احتمالية الإصابة بالخرف في السيدات اللاتي يبلغن من العمر ٦٥ عامًا أو أكبر في المرحلة التالية لانقطاع الطمث. وبالإضافة إلى ذلك، فإن العلاج باستخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا لم يمنع حدوث خلل إدراكي خفيف (MCI) لدى تلك السيدات. يوصى بعدم استخدام العلاج الهرموني لمنع الإصابة بالخرف أو الخلل الإدراكي الخفيف في السيدات اللاتي يبلغن من العمر ٦٥ سنة أو أكبر.</p><p dir="RTL"><u>سرطان المبيض</u></p><p dir="RTL">في بعض الدراسات الوبائية، تم ربط الاستخدام الحالي للإستروجين سواء كان بمفرده أو مع منتجات البروجستين في السيدات في المرحلة التالية لانقطاع الطمث لمدة خمس سنوات أو أكثر بزيادة خطر الإصابة بسرطان المبيض. ولم تكن هناك زيادة في خطر الإصابة بسرطان المبيض في المستخدمات السابقات للإستروجين بمفرده أو مع منتجات البروجستين. ولم تظهر الدراسات الأخرى وجود ارتباط مهم. أفادت تجربة مبادرة صحة المرأة التي أجريت على استخدام الإستروجينات المقترنة الخيلية مع ديبو بروفيرا بأن استخدام الإستروجين مع البروجستين زاد من خطر الإصابة بسرطان المبيض، ولكن هذا الخطر لم يكن ذا دلالة إحصائية. وفي دراسة واحدة، وُجد أن السيدات اللاتي يخضعن للعلاج بالهرمونات البديلة (HRT) يزداد خطر إصابتهن بسرطان المبيض المميت.</p><p dir="RTL"><u>التوصيات الخاصة بالتاريخ الطبي والفحص البدني</u></p><p dir="RTL">ينبغي الاطلاع على التاريخ الطبي والأسري بالكامل قبل بدء أي علاج هرموني. وينبغي أن تتضمن الفحوصات التي تُجرى قبل مرحلة العلاج والفحوصات البدنية الدورية إشارة بشكل خاص لحالة ضغط الدم والثديين والبطن وأعضاء الحوض، بما في ذلك، دراسة لخلايا عنق الرحم.</p><p><em>&nbsp;</em></p><p><em>طب أمراض النساء-التركيبات القابلة للحقن</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث عدم تبويض لفترة طويلة مع انقطاع للحيض و/أو أنماط حيضية غير منتظمة بعد إعطاء جرعة واحدة أو جرعات متعددة من ديبو بروفيرا القابل للحقن.</p><p><em>&nbsp;</em></p><p><em>طب الأورام</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يتسبب ديبو بروفيرا في ظهور الأعراض كوشينغية الشكل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تعاني بعض المريضات اللاتي يتلقين ديبو بروفيرا من تثبيط في وظيفة الغدة الدرقية. يمكن أن يخفض ديبو بروفيرا من مستويات الهرمون الموجه لقشر الكظر والهيدروكورتيزون في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي إخبار الطبيب/المعمل أنه بالإضافة إلى المؤشرات الحيوية للغدد الصماء، فإن استخدام ديبو بروفيرا لدواعي الاستعمال ذات الصلة بطب الأورام يمكن أن يتسبب أيضًا في حدوث قصور جزئي في الغدة الكظرية (انخفاض في استجابة محور الغدة النخامية-الغدة الكظرية) أثناء اختبار ميتيرابون. ولذلك فإنه ينبغي أن يتم إثبات قدرة قشرة الغدة الكظرية على الاستجابة للهرمون الموجه لقشرة الكظر قبل إعطاء ميتيرابون.</p><p><em>&nbsp;</em></p><p><em>طب الأورام-التركيبات القابلة للحقن</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث عدم تبويض لفترة طويلة مع انقطاع للحيض و/أو أنماط حيضية غير منتظمة بعد إعطاء جرعة واحدة أو جرعات متعددة من ديبو بروفيرا القابل للحقن.</p><p><em>التركيبات التي تؤخذ عبر الفم والتركيبات التي تؤخذ عن طريق الحقن الخاصة بالجرعة العالية (مثل تلك المستخدمة في طب الأورام في السيدات في المرحلة السابقة لانقطاع الطمث) </em></p><p dir="RTL"><u>انخفاض الكثافة المعدنية للعظم</u></p><p dir="RTL">لا توجد دراسات على آثار استخدام ديبو بروفيرا الذي يعطى عبر الفم أو الجرعات العالية التي تعطى عن طريق الحقن من ديبو بروفيرا (مثل المُستخدمة في طب الأورام) على الكثافة المعدنية للعظم. وقد يكون من الملائم إجراء تقييم للكثافة المعدنية للعظم في بعض المريضات اللاتي يستخدمن ديبو بروفيرا لفترة طويلة الأمد، (<strong>انظر أعلاه - فقدان الكثافة المعدنية للعظم</strong>).&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقات</strong></p><p dir="RTL">حقن ديبو بروفيرا التي تُعطى عن طريق العضل غير مخصصة للاستخدام قبل بدء الحيض. ولكن تتوفر بيانات عن الفتيات المراهقات (من ١٢‑١٨ سنة). من المتوقع أن تكون سلامة وفعالية ديبو بروفيرا الذي يحقن عن طريق العضل مماثلة بالنسبة لكل من الفتيات المراهقات والبالغات في المرحلة التالية لبدء الحيض</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبري طبيبكِ أو الصيدلي إذا كنتِ تتلقين أو قد تلقيتِ مؤخرًا أو قد تتلقين أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم أيض أسيتات ميدروكسي بروجستيرون (ديبو بروفيرا) بشكل رئيسي في المعمل من خلال إضافة الهيدروكسيل عن طريق CYP3A4. لم يتم إجراء دراسات خاصة على التفاعلات الدوائية لتقييم الآثار الإكلينيكية لمحفزات أو مثبطات CYP3A4 على ديبو بروفيرا، ولذلك فإن الآثار الإكلينيكية لمحفزات أو مثبطات CYP3A4 غير معروفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong></p><p dir="RTL">يمنع استعمال ديبو بروفيرا مع السيدات الحوامل.&nbsp;</p><p dir="RTL">تشير بعض التقارير، أنه في ظل ظروف معينة، يكون هناك ارتباط بين التعرض داخل الرحم للعقاقير البروجستيرونية خلال الثلث الأول من الحمل والعيوب التناسلية في الأجنة.</p><p dir="RTL">الأطفال الرضع الذين ولدوا نتاج حمل غير مقصود حدث بعد حقن معلق ديبو بروفيرا القابل للحقن بفترة تتراوح بين شهر وشهرين، قد يعانون من زيادة خطر قلة الوزن عند الولادة، الذي يرتبط بدوره بزيادة خطر الوفاة بين حديثي الولادة. إن انخفاض الخطر المعزوّ يرجع إلى أن حدوث الحمل أثناء استخدام ديبو بروفيرا هو أمر غير شائع.&nbsp; لا توجد معلومات حاسمة بشأن التركيبات الأخرى لديبو بروفيرا.</p><p dir="RTL">إذا أصبحت المريضة حاملًا أثناء استخدام هذا العقار، ينبغي أن تكون المريضة على علم بالخطر المحتمل على الجنين.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الرضاعة</strong><strong> الطبيعية</strong></p><p dir="RTL">يتم إفراز ديبو بروفيرا ونواتج أيضه في لبن الثدي. ولا يوجد أي دليل يقترح أن هذا الأمر يشكل أي خطر على الطفل الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ديبو بروفيرا على القيادة واستخدام الآلات</strong></p><p dir="RTL">لم يتم تقييم أثر أسيتات ميدروكسي بروجستيرون بشكل منهجي على القدرة على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي رج المعلقات القابلة للحقن جيدًا قبل الاستخدام.</p><p><em>&nbsp;</em></p><p><strong><em>منع الحمل</em></strong></p><p dir="RTL">ينبغي رج معلقات ديبو بروفيرا القابلة للحقن عن طريق العضل بقوة قبل الاستخدام مباشرةً للتأكد من أن الجرعة التي يتم إعطاؤها تمثل معلقًا متجانسًا.<strong><em>&nbsp; </em></strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>للاستخدام عن طريق العضل </u></p><p dir="RTL">الجرعة الموصى بها هي ١٥٠ ملجم من معلق ديبو بروفيرا القابل للحقن كل ٣ أشهر (من ١٢‑١٣ أسبوعًا) عن طريق العضل في العضلة الألوية أو العضلة الضامة.&nbsp; لا توجد تركيبة من معلق الحقن عن طريق العضل تستخدم في الحقن تحت الجلد.<sup>&nbsp; </sup></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الحقنة الأولى </em></p><p dir="RTL">ينبغي إعطاء الحقنة الأولى عن طريق العضل خلال الـ٥ أيام الأولى بعد بدء فترة الحيض المعتادة؛ أو خلال الـ٥ أيام الأولى من فترة ما بعد الولادة إذا لم تكن المريضة ترضع طبيعيًا؛ أو، إذا كانت ترضع طبيعيًا فقط، ينبغي إعطاؤها في الأسبوع السادس من فترة ما بعد الولادة أو بعد ذلك.</p><p dir="RTL"><em>الحقنة الثانية والحقن التالية</em></p><p dir="RTL">إذا كانت الفترة الزمنية الفاصلة بين استخدام الحقن عن طريق العضل أكبر من ١٣ أسبوعًا، ينبغي التأكد من عدم حدوث حمل قبل إعطاء الحقنة التالية عن طريق العضل.</p><p dir="RTL">&nbsp; <em>استبدال وسائل منع الحمل الأخرى بديبو بروفيرا </em></p><p dir="RTL">عند استبدال وسائل منع الحمل الأخرى بديبو بروفيرا، ينبغي إعطاء (ديبو بروفيرا للحقن عن طريق العضل) بطريقة تضمن تأمينًا متواصلًا لمنع الحمل وفقًا لآلية عمل كل من الوسيلتين (على سبيل المثال، ينبغي أن يتم إعطاء المريضات اللاتي يستبدلن وسائل منع الحمل التي تؤخذ عبر الفم بديبو-بروفيرا حقنتهن الأولى منه في غضون ٧ أيام بعد تناول آخر حبة فعالة من حبوب منع الحمل).</p><p><em>&nbsp;</em></p><p><strong><em>طب أمراض النساء</em></strong></p><p dir="RTL">ينبغي أن يقتصر استخدام علاج الإستروجين/البروجستين المركب في السيدات في المرحلة التالية لانقطاع الطمث على أقل جرعة فعالة ولأقصر مدة بما يتسق مع الأهداف العلاجية والمخاطر بالنسبة لكل سيدة بشكل فردي، وينبغي تقييمه بشكل دوري.</p><p dir="RTL">يوصى بإجراء فحوصات دورية وتحديد معدل تكرار وطبيعة هذه الفحوص وفقًا لكل سيدة.</p><p dir="RTL">ما لم يكن هناك تشخيص سابق للإصابة بانتباذ بطانة الرحم، فإنه لا يوصى بإضافة البروجستين لاستخدامه مع السيدات اللاتي ليس لديهن رحمًا سليمًا.</p><p><u>&nbsp;</u></p><p><u>انتباذ بطانة الرحم</u><strong><u> </u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعطى ٥٠ ملجم أسبوعيًا أو ١٠٠ ملجم كل أسبوعين لمدة ٦ أشهر على الأقل من ديبو بروفيرا القابل للحقن من خلال الحقن عن طريق العضل.</p><p><u>الأعراض الوعائية الحركية المصاحبة لانقطاع الحيض</u><strong><u> </u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعطى ١٥٠ ملجم من ديبو بروفيرا القابل للحقن مرة كل ١٢ أسبوعًا من خلال الحقن عن طريق العضل.</p><p><em>&nbsp;</em></p><p><strong><em>طب الأورام</em></strong></p><p><u>سرطان الثدي المتكرر و/أو النقيلي</u><em> </em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح الجرعة المبدئية من ديبو بروفيرا بين ٥٠٠ ملجم و١٠٠٠ ملجم تؤخذ من خلال الحقن عن طريق العضل يوميًا لمدة ٢٨ يومًا. وبعد ذلك ينبغي وضع المريضة في جدول مداومة يتضمن استخدام ٥٠٠ ملجم مرتين أسبوعيًا طالما تستجيب للعلاج.</p><p><u>&nbsp;</u></p><p><u>سرطان الكلى أو سرطان بطانة الرحم متكرر الظهور و/أو النقيلي</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوصى بالبدء باستخدام جرعة تتراوح بين ٤٠٠ ملجم و١٠٠٠ ملجم أسبوعيًا من ديبو بروفيرا القابل للحقن وتؤخذ عن طريق الحقن في العضل. وإذا حدث تحسن خلال الأسابيع القليلة الأولى أو الأشهر القليلة الأولى وبدا أن المرض مستقر، فإنه من الممكن الحفاظ على مستوى التحسن الذي حدث باستخدام كمية قليلة تصل إلى ٤٠٠ ملجم شهريًا. <u>&nbsp;</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>القصور الكبدي</u></p><p dir="RTL">لم تُجرى أي دراسات إكلينيكية لتقييم أثر المرض الكبدي على الحرائك الدوائية لديبو بروفيرا. ومع ذلك، فإنه يتم إطراح ديبو بروفيرا بشكل حصري تقريبًا عبر الأيض الكبدي وقد يتم أيض الهرمونات الستيرويدية بشكل ضعيف في حالات المريضات اللاتي يعانين من القصور الكبدي.</p><p><u>القصور الكلوي</u><strong> </strong></p><p dir="RTL">لم تقيم أي دراسات إكلينيكية أثر المرض الكلوي على الحرائك الدوائية لديبو بروفيرا. ومع ذلك، نظرًا لأنه يتم إطراح ديبو بروفيرا بشكل حصري تقريبًا عبر الأيض الكبدي، فلن تكون هناك حاجة إلى تعديل الجرعة في حالات السيدات اللاتي يعانين من القصور الكلوي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقات</strong></p><p dir="RTL">حقن ديبو بروفيرا التي تُعطى عن طريق العضل غير مخصصة للاستخدام قبل بدء الحيض. ولكن تتوفر بيانات عن الفتيات المراهقات (من ١٢‑١٨ سنة). من المتوقع أن تكون سلامة وفعالية ديبو بروفيرا الذي يحقن عن طريق العضل مماثلة بالنسبة لكل من الفتيات المراهقات والبالغات في المرحلة التالية لبدء الحيض</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة ديبو بروفيرا</strong></p><p dir="RTL">إذا كانت الفترة الزمنية الفاصلة بين استخدام الحقن عن طريق العضل أكبر من ١٣ أسبوعًا، ينبغي التأكد من عدم حدوث حمل قبل إعطاء الحقنة التالية عن طريق العضل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التوقف عن تناول ديبو بروفيرا</strong></p><p dir="RTL">إذا كان لديكِ أي أسئلة إضافية حول استخدام هذا الدواء، فاسألي طبيبكِ أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL"><sub>&nbsp;</sub></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتساب الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بالمعدة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة:</strong> (قد تصيب شخصًا واحدًا إلى ١٠ أشخاص من بين كل ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفرازات المهبل (إفرازات بيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضغط في الثديين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب شخصًا واحدًا إلى ١٠ أشخاص من بين كل ١٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية تجاه الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نمو الشعر بالجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبلي خارج أيام الدورة الشهرية: نزيف غير منتظم، أو غير متوقع، أو زائد، أو منخفض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الحوض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدرار اللبن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الانصمام الخثاري (أمراض يحدث فيها انسداد للأوعية الدموية بسبب الجلطات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد الخثاري (التهاب بأحد الأوردة مصحوب بجلطة دموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم/حساسية في موضع الحقن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقديرها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الثديين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة يحتمل أن تصبح ذات نتائج مميتة (التأق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الوعائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانقطاع المطول للتبويض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الوصول لهزة الجماع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حثل شحمي مكتسب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع الدورة الشهرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل بموضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان/تجوف/ تنقر الأنسجة في موضع الحقن بشكل مستديم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقد/تورم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القدرة على تحمل السكر (الجلوكوز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الكثافة المعدنية للعظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجه بدري (وجه مستدير، أحمر، متورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انصمام رئوي (مرض يحدث فيه انسداد للأوعية الدموية للرئتين بسبب الجلطات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هشاشة العظام (نقص كتلة العظام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور ناتجة عن الهشاشة ذات صلة بهشاشة العظام</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبتِ بأي آثار جانبية، فتحدثي إلى طبيبكِ أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا أصبتِ بأي آثار جانبية، فتحدثي إلى طبيبكِ أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنكِ أيضًا الإبلاغ عن الآثار الجانبية مباشرة. بالإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https//ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:355px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظي بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة حرارة أقل من ٣٠ درجة مئوية.<br />لا يجمد ولا يوضع في الثلاجة.</p><p dir="RTL">تخزن القارورة في وضع رأسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمي هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق، العبوة الكرتونية - يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر - .</p><p dir="RTL">&nbsp;<br />صلاحية المستحضر ٤٨ شهر.<br />&nbsp;</p><p dir="RTL">لا تستخدمي هذا الدواء إذا لاحظتِ {وصف العلامات المرئية التي تدل على التلف}.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلصي من أي أدوية عبر مياه الصرف. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي تستخدمينها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة (المواد) الفعالة هي: أسيتات ميدروكسي بروجستيرون&lrm;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكون (المكونات) الأخرى: ماكروجول ٣٣٥٠، بوليسوربات ٨٠، كلوريد الصوديوم، بارا هيدروكسي بنزوات الميثيل ، بارا هيدروكسي بنزوات البروبيل ، ماء للحقن، حمض الهيدروكلوريك و/أو هيدروكسيد الصوديوم لضبط درجة الحموضة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">معلق مائي معقم للحقن عن طريق العضل.</p><p dir="RTL"><u>الأشكال</u>:</p><p dir="RTL">مُعلق ديبو-بروفيرا ١٥٠ ملجم مخصص للحقن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قارورة ٣٫٣ مل</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer S.A., 17 Boulevard de la Plaine, 1050 Brussels, Belgium</p><p dir="RTL">بلجيكا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium</p><p dir="RTL">بلجيكا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/كانون الأول ٢٠٢٣  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DEPO-PROVERA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injectable suspension 
Depot-medroxyprogesterone acetate (DEPO PROVERA) injectable suspension is available in vials as  500 mg/3.3 mL.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injectable: Suspension for intramuscular (IM) injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Contraception</em></p><p>Depo Provera injectable suspensions (IM )are indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contraception</p><p><em>Gynecology</em></p><p>Depo Provera injectable IM suspension is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of endometriosis</p><p>Depo Provera injectable IM suspension is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of menopausal vasomotor symptoms</p><p><em>Oncology</em></p><p>Depo Provera injectable IM suspension is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic endometrial cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent and/or metastatic renal cancer</p><p>&nbsp;</p><p><em>Long-term Use </em></p><p>Since loss of bone mineral density (BMD) may occur in pre-menopausal women who use Depo Provera injection long-term (<strong>see Section 4.4.</strong> <strong>Special warnings and precautions for use</strong> - <strong>Additional Warnings and Precautions for Specific Use or Formulation, <em>Contraception/Endometriosis - Injectable Formulations</em>: </strong>Loss of Bone Mineral Density and<strong> Section 5.1. Pharmacodynamic properties - <em>Clinical Studies</em>, </strong><u>Bone Mineral Density Studies</u>), a risk/benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered.</p><p><em>Use in Children</em></p><p>Depo Provera IM is not indicated before menarche. Data are available in adolescent females (12‑18&nbsp;years)<strong> </strong>(<strong>see Section 5.1.</strong> <strong>Pharmacodynamic properties - <em>Clinical Studies</em>, </strong><em>BMD Changes in Adolescent Females (12-18 years<strong>)</strong></em>. The safety and effectiveness of Depo Provera IM are expected to be the same for postmenarcheal adolescent and adult females.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>injectable suspensions should be shaken well before use.</p><p><em>Contraception</em></p><p>Depo Provera intramuscular (IM) injectable suspensions should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.<strong><em>&nbsp; </em></strong></p><p><u>Intramuscular (IM) </u></p><p>The recommended dose is 150 mg of&nbsp; Depo Provera injectable suspension every 3 months (12‑13&nbsp;weeks) administered by intramuscular injection in the gluteal or deltoid muscle.&nbsp; The IM suspension is not formulated for subcutaneous injection.<sup>&nbsp; </sup></p><p><em>First injection </em></p><p>The initial IM injection should be given during the first 5 days after the onset of a normal menstrual period; within 5&nbsp;days postpartum if not breast-feeding; or, if exclusively breast-feeding, at or after 6 weeks postpartum.</p><p><em>Second and subsequent injections</em></p><p>If the time interval between IM injections is greater than 13 weeks, pregnancy should be ruled out before administering the next IM injection.</p><p><em>Switching from other methods of contraception </em></p><p>When switching from other contraceptive methods, (Depo Provera IM) should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods (e.g., patients switching from oral contraceptives should have their first injection of Depo Provera within 7 days after taking their last active pill).</p><p><em>Gynecology</em></p><p>Use of combined estrogen/progestin therapy in postmenopausal women should be limited to the lowest effective dose and shortest duration consistent with treatment goals and risks for the individual woman, and should be periodically evaluated. <strong>&nbsp;</strong>(<strong>see Section 4.4 &ndash; Special warnings and precautions for use.</strong>)<strong> </strong></p><p>Periodic check-ups are recommended with a frequency and nature adapted to the individual woman.&nbsp; (<strong>see Section 4.4 &ndash; Special warnings and precautions for use</strong>.)</p><p>Unless there is a previous diagnosis of endometriosis, it is not recommended to add a progestin in a woman without an intact uterus.</p><p><u>Endometriosis</u><u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo Provera, given intramuscularly 50 mg weekly or 100 mg every 2 weeks for at least 6 months.</p><p><u>Menopausal Vasomotor Symptoms</u><u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo Provera given intramuscularly 150 mg every 12 weeks.</p><p><em>Oncology</em></p><p><u>Recurrent and/or Metastatic Breast Cancer</u><em> </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo Provera initial dose 500 to 1000 mg intramuscularly per day for 28 days. The patient should then be placed on a maintenance schedule of 500 mg twice weekly as long as she responds to treatment.</p><p><u>Recurrent and/or Metastatic Endometrial or Renal Cancer</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable Depo Provera 400 to 1000 mg intramuscularly per week is recommended initially. If improvement is noted within a few weeks or months and the disease appears stabilized, it may be possible to maintain improvement with as little as 400 mg per month.</p><p>&nbsp;<u>Hepatic Insufficiency</u></p><p>No clinical studies have evaluated the effect of hepatic disease on the pharmacokinetics of Depo Provera. However, Depo Provera is almost exclusively eliminated by hepatic metabolism and steroid hormones may be poorly metabolized in patients with severe liver insufficiency (<strong>see&nbsp;Section</strong>&nbsp;<strong>4.3. Contraindications</strong>).</p><p><u>Renal Insufficiency</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No clinical studies have evaluated the effect of renal disease on the pharmacokinetics of Depo Provera. However, since Depo Provera is almost exclusively eliminated by hepatic metabolism, no dosage adjustment should be necessary in women with renal insufficiency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Depo Provera is contraindicated in patients with the following conditions:
•	Known or suspected pregnancy 
•	Undiagnosed vaginal bleeding 
•	Severe liver dysfunction 
•	Known hypersensitivity to Depo Provera or any component of the drug
Additional Contraindication(s) for Specific Use
Contraception/Gynecology: Known or suspected malignancy of the breast 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>General</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unexpected vaginal bleeding during therapy with Depo Provera should be investigated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo Provera may cause some degree of fluid retention, therefore, caution should be exercised in treating any patient with a pre-existing medical condition that might be adversely affected by fluid retention.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a history of treatment for clinical depression should be carefully monitored while receiving Depo Provera therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients receiving Depo Provera may exhibit a decreased glucose tolerance. Diabetic patients should be carefully observed while receiving such therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pathologist (laboratory) should be informed of the patient&rsquo;s use of Depo Provera if endometrial or endocervical tissue is submitted for examination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The physician/laboratory should be informed that use of Depo Provera may decrease the levels of the following endocrine biomarkers:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma/urinary steroids (e.g., cortisol, estrogen, pregnanediol, progesterone, testosterone)</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma/urinary gonadotrophins (e.g., luteinizing hormone (LH) and follicle-stimulating hormone (FSH)</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sex hormone-binding-globulin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medication should not be readministered, pending examination, if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilloedema or retinal vascular lesions, medication should not be readministered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo Provera has not been causally associated with the induction of thrombotic or thromboembolic disorders , however, Depo Provera is not recommended in any patient with a history of venous thromboembolism (VTE). Discontinuation of DEPO PROVERA is recommended in patients who develop VTE while undergoing therapy with DEPO PROVERA.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meningiomas have been reported following long term administration of progestins, including MPA. MPA should be discontinued if a meningioma is diagnosed. Caution is advised when recommending medroxyprogesterone to patients with a history of meningioma.</p><p>&nbsp;</p><p><em>Additional Warnings and Precautions for Specific Use or Formulation</em></p><p><u>Contraception/Endometriosis - Injectable Formulations</u></p><p><u>Loss of Bone Mineral Density (BMD) </u></p><p>Use of DEPO PROVERA injection reduces serum estrogen levels in premenopausal women and is associated with a statistically significant loss of BMD as bone metabolism accommodates to a lower estrogen level. Bone loss may be greater with increasing duration of use and may not be completely reversible in some women. It is unknown if use of DEPO PROVERA injection during adolescence and early adulthood, a critical period of bone accretion, will reduce peak bone mass. In both adult <sup>&nbsp;</sup>and adolescent females , the decrease in BMD during treatment appears to be substantially reversible after DEPO PROVERA injection is discontinued and ovarian estrogen production increases&nbsp; (see <strong>Section 5.1 &ndash; Pharmacodynamic Properties, <em>Clinical Studies,</em></strong> <u>BMD Studies</u>). After discontinuing Depo-Provera injection in adolescents, full recovery of mean BMD required 1.2 years at the lumbar spine, 4.6 years at the total hip and 4.6 years at the femoral neck (see <strong>Section 5.1 &ndash; Pharmacodynamic Properties, <em>Clinical Studies,</em> </strong><u>BMD Studies</u> - BMD recovery post-treatment in adolescent women).<em> </em></p><p>In adults, BMD was observed for a period of 2 years after DEPO PROVERA injection was discontinued and partial recovery of mean BMD towards baseline was observed at total hip, femoral neck and lumbar spine (see <strong>Section 5.1 &ndash; Pharmacodynamic Properties, <em>Clinical Studies,</em></strong> <u>BMD Studies - </u>BMD Changes in Adult Women). A large observational study of female contraceptive users showed that use of Depo-Provera injection has no effect on a woman&rsquo;s risk for osteoporotic or non-osteoporotic fractures (see <strong>Section 5.1 &ndash; Pharmacodynamic Properties, <em>Clinical Studies,</em> </strong><u>BMD Studies - </u>Relationship of fracture incidence to use of DEPO PROVERA injectable (150 mg IM) or non-use by women of reproductive age).</p><p>&nbsp;</p><p><em>BMD Changes in Adult Women after Six Months of Treatment for Endometriosis </em></p><p>In two clinical studies of 573 adult women with endometriosis, the BMD effects of 6&nbsp;months of DEPO PROVERA SC treatment were Compared to 6 months of leuprolide treatment.&nbsp; Subjects were then observed, off therapy, for an additional 12 months.&nbsp;</p><p>The proportion of patients with a decrease of 5% or more in BMD was statistically significantly greater in the leuprolide group Compared with DEPO PROVERA-SC at each time point (Table 1).&nbsp;</p><p>Table&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of Patients with a Decrease of 5% or More from Baseline after 6&nbsp;Months on Therapy with DEPO PROVERA-SC or Leuprolide and 6 Months after Stopping Therapy (Studies 268 and 270 Combined)</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>BMD Parameter</p></td><td style="vertical-align:top"><p>DEPO PROVERA-SC<br />n/N* (%)</p></td><td style="vertical-align:top"><p>Leuprolide<br />n/N* (%)</p></td><td style="vertical-align:top"><p>p-value**</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>End of Treatment (6 Months of Therapy)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Spine</p></td><td style="vertical-align:top"><p>12/208 (5.8%)</p></td><td style="vertical-align:top"><p>85/229 (37.1%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Total Hip</p></td><td style="vertical-align:top"><p>1/207 (0.5%)</p></td><td style="vertical-align:top"><p>25/227 (11.0%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>At 12 Month Visit (6 Months Off-Therapy)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Spine</p></td><td style="vertical-align:top"><p>8/166 (4.8%)</p></td><td style="vertical-align:top"><p>32/178 (18.0%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Total Hip</p></td><td style="vertical-align:top"><p>3/166 (1.8%)</p></td><td style="vertical-align:top"><p>25/178 (14.0%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>* n=number of patients with a decrease in BMD &sup3;5%; N=total observations</p><p>** chi-square</p><p>Other birth control methods or endometrial treatments should be considered in the risk/benefit analysis for the use of DEPO PROVERA injection in women with osteoporotic risk factors such as:&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic alcohol and/or tobacco use</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic use of drugs that can reduce bone mass, e.g., anticonvulsants or corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low body mass index (BMI) or eating disorder, e.g., anorexia nervosa or bulimia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic bone disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong family history of osteoporosis</p><p>It is recommended that all patients have adequate calcium and Vitamin D intake.</p><p><em>Contraception </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most women using DEPO PROVERA injectable suspension experience disruption of menstrual bleeding patterns (e.g., irregular or unpredictable bleeding/spotting, rarely, heavy or continuous bleeding). As women continue using DEPO PROVERA injectable suspension, fewer experience irregular bleeding and more experience amenorrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term case-controlled surveillance of users of DEPO PROVERA injectable suspension found slight or no increased overall risk of breast cancer&nbsp; and no overall increased risk of ovarian,&nbsp; liver,&nbsp; or cervical&nbsp; cancer and a prolonged, protective effect of reducing the risk of endometrial&nbsp; cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEPO PROVERA IM injectable suspension has a prolonged contraceptive effect. The median time to contraception following the last injection, for those who do conceive, is 10 months, with a range of 4 to 31 months, and is unrelated to the duration of use.</p><p>There was a tendency for women to gain weight while on therapy with DEPO PROVERA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If jaundice develops, consideration should be given to not readminister the drug.</p><p><u>Sexually Transmitted Infections </u></p><p>Women should be counseled that DEPO PROVERA injectable suspension does not protect against sexually transmitted infections (STIs) including HIV infection (AIDS) but equally, DEPO PROVERA is a sterile injection and, used as directed, will not expose them to sexually transmitted infections. Safer sex practices including correct and consistent use of condoms reduce the transmission of STIs through sexual contact, including HIV.</p><p><u>Breast Cancer </u></p><p>See below.</p><p><em>Gynecology</em></p><p><u>Treatment of Menopausal Vasomotor Symptoms/Opposition of Endometrial Effects of Estrogen in Menopausal Women Being Treated with Estrogen (Hormone Therapy)-All Formulations</u><u>:&nbsp; </u></p><p>Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of Hormone Therapy (HT) were not studied in the Women&rsquo;s Health Initiative (WHI) trial (<strong>see Section 5.1 &ndash; Pharmacodynamic Properties, <em>Clinical Studies</em>, </strong><u>Women&rsquo;s Health Initiative Study</u>) and, in the absence of comparable data, these risks should be assumed to be similar.</p><p><u>Breast Cancer </u></p><p>The use of combined oral estrogen/progestin by postmenopausal women has been reported to increase the risk of breast cancer.&nbsp; Results from a randomized placebo-controlled trial, the WHI trial, and epidemiological studies (<strong>see Section 5.1 - Pharmacodynamic properties, <em>Clinical Studies</em></strong>) have reported an increased risk of breast cancer in women taking estrogen/progestin combinations for HT for several years. In the WHI conjugated equine estrogens (CEE) plus DEPO PROVERA trial and observational studies, the excess risk increased with duration of use &nbsp;(<strong>see Section 4.2 - Posology and method of administration</strong>). The use of estrogen plus progestin has also been reported to result in an increase in abnormal mammograms requiring further evaluation.</p><p>In several epidemiologic studies no overall increased risk for breast cancer was found among users of injectable depot progestogens in comparison to non-users. <strong>&nbsp;</strong>However, an increased relative risk (e.g. 2.0 in one study) was found for women who currently used injectable depot progestogens or had used them only a few years before.&nbsp; It is not possible to infer from these data whether this increased rate of breast cancer diagnosis among current users is due to increased surveillance among current users, the biological effects of injectable progestogens, or a combination of reasons.</p><p><u>Cardiovascular Disorders</u></p><p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. Several randomized, prospective trials on the long-term effects <strong>(see Section&nbsp;4.2. Posology and method of administration</strong>), of a combined estrogen/progestin regimen in postmenopausal women have reported an increased risk of cardiovascular events such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coronary Artery Disease</p><p>There is no evidence from randomized controlled trials of cardiovascular benefit with continuous combined conjugated estrogen and medroxyprogesterone acetate (DEPO PROVERA). Two large clinical trials [WHI CEE/DEPO PROVERA and Heart and Estrogen/progestin Replacement Study (HERS) (<strong>see Section 5.1 - Pharmacodynamic properties, <em>Clinical Studies</em></strong>) showed a possible increased risk of cardiovascular morbidity in the first year of use and no overall benefit.<sup> </sup></p><p>In the WHI CEE/DEPO PROVERA trial, an increased risk of coronary heart disease (CHD) events (defined as nonfatal myocardial infarction and CHD death) was observed in women receiving CEE/DEPO PROVERA compared to women receiving placebo (37 vs. 30 per 10,000 person years). The increase in VTE risk was observed in year one and persisted over the observation period (<strong>see Section 4.2 &ndash; Posology and method of administration</strong>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke</p><p>In the WHI CEE/DEPO PROVERA trial, an increased risk of stroke was observed in women receiving CEE/DEPO PROVERA compared to women receiving placebo (29 vs. 21 per 10,000 person-years). The increase in risk was observed in year one and persisted over the observation period (<strong>see Section 4.2 - Posology and method of administration</strong>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolism / Pulmonary embolism</p><p>HT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e., deep vein thrombosis or pulmonary embolism. In the WHI CEE/DEPO PROVERA trial, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism was observed in women receiving CEE/DEPO PROVERA compared to women receiving placebo.&nbsp; The increase in risk was observed in year one and persisted over the observation period (<strong>see Section </strong><strong>4.4-Special warnings and precautions for use</strong>).</p><p><u>Dementia</u></p><p>The Women&rsquo;s Health Initiative Memory Study (WHIMS) (<strong>see Section 5.1 Pharmacodynamic Properties - <em>Clinical Studies</em></strong>), an ancillary study of WHI, CEE/DEPO PROVERA reported an increased risk of probable dementia in postmenopausal women 65 years of age or older. In addition, CEE/DEPO PROVERA therapy did not prevent mild cognitive impairment (MCI) in these women. Use of hormone therapy (HT) to prevent dementia or MCI in women 65 years or older is not recommended.</p><p><u>Ovarian Cancer</u></p><p>Current use of estrogen only or estrogen plus progestin products in post-menopausal women for five or more years, has been associated with an increased risk of ovarian cancer in some epidemiological studies. <strong>[110]</strong> Past users of estrogen only or estrogen plus progestin products were at no increased risk for ovarian cancer. <strong>[110]</strong> Other studies did not show a significant association.&nbsp; The WHI CEE/DEPO PROVERA trial reported that estrogen plus progestin increased the risk of ovarian cancer, but this risk was not statistically significant. In one study, women who use HRT are at increased risk of fatal ovarian cancer.</p><p><u>History and Physical Exam Recommendation</u></p><p>A complete medical and family history should be taken before the initiation of any hormone therapy. Pretreatment and periodic physical examinations should include special reference to blood pressure, breasts, abdomen, and pelvic organs, including cervical cytology.</p><p><em>Gynecology-Injectable Formulations</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged anovulation with amenorrhoea and/or erratic menstrual patterns may follow the administration of either a single or multiple injectable dose of DEPO PROVERA.</p><p><em>Oncology</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEPO PROVERA may produce Cushingoid symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients receiving DEPO PROVERA may exhibit suppressed adrenal function. DEPO PROVERA may decrease ACTH and hydrocortisone blood levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The physician/laboratory should be informed that in addition to the endocrine biomarkers listed in <strong>Section 4.4. Special warnings and precautions for use</strong>, the use of DEPO PROVERA in oncology indications may also cause partial adrenal insufficiency (decrease in pituitary-adrenal axis response) during metyrapone testing. Thus the ability of adrenal cortex to respond to ACTH should be demonstrated before metyrapone is administered.</p><p><em>Oncology-Injectable Formulations</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged anovulation with amenorrhoea and/or erratic menstrual patterns may follow the administration of either a single or multiple injectable dose of DEPO PROVERA.</p><p><em>High Dose Parenteral Formulations (e.g., oncology use in pre-menopausal women) </em></p><p><u>Decrease in Bone Mineral Density</u></p><p>There are no studies on the bone mineral density (BMD) effects of orally administered DEPO PROVERA or the high doses of parenteral DEPO PROVERA (e.g., for oncology use). An evaluation of BMD may be appropriate in some patients who use DEPO PROVERA long-term , (<strong>see above &ndash; Loss of Bone Mineral Density</strong>).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medroxyprogesterone acetate (DEPO PROVERA) is metabolized in-vitro primarily by hydroxylation via the CYP3A4.&nbsp; Specific drug-drug interaction studies evaluating the clinical effects with CYP3A4 inducers or inhibitors on DEPO PROVERA have not been conducted and therefore the clinical effects of CYP3A4 inducers or inhibitors are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>DEPO PROVERA is contraindicated in women who are pregnant. &nbsp;</p><p>Some reports suggest under certain circumstances, an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in fetuses.</p><p>Infants from unintentional pregnancies that occur 1 to 2 months after injection of DEPO PROVERA injectable suspension may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal death. The attributable risk is low because pregnancies while on DEPO PROVERA are uncommon.&nbsp; There is no definitive information for the other formulations of DEPO PROVERA, (<strong>see Section 5.2 Pharmacokinetic properties - <em>Intramuscular formulations: </em></strong>Distribution).</p><p>If the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus.</p><p><em>Lactation</em></p><p>DEPO PROVERA and its metabolites are excreted in breast milk. There is no evidence to suggest that this presents any hazard to the nursing child <strong>,</strong> (<strong>see Section 5.2, Pharmacokinetic properties, <em>Intramuscular formulations: </em></strong>Distribution).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of medroxyprogesterone acetate on the ability to drive and use machinery has not been systematically evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraception- Intramuscular (IM) Formulation [Appendix A, Appendix B]:</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Drug Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, anaphylactoid reaction, angioedema, drug hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression, insomnia, nervousness, anorgasmia, libido decreased</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Seizure, dizziness, headache, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism and thrombosis, hot flush</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain, abdominal discomfort, nausea, abdominal distension</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Jaundice, liver disorder</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia, acne, hirsutism, urticaria, lipodystrophy acquired<sup>*</sup>,<strong> </strong>pruritus, rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue&nbsp; disorders</p></td><td style="vertical-align:top"><p>Arthralgia, back pain, muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting), galactorrhoea, pelvic pain, vaginitis, amenorrhoea, breast pain, vaginal discharge, breast tenderness</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fluid retention, pyrexia, fatigue, asthenia, injection-site reaction<sup>*</sup>, injection site persistent atrophy/indentation/dimpling<sup>*</sup>, injection site nodule/lump<sup>*</sup>, injection site pain/tenderness<sup>*</sup><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Bone density decreased, glucose tolerance decreased, weight increased, weight decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*ADR identified post-marketing</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional Adverse Events Reported During Post-Marketing Experience:</p><p><em>Intramuscular Formulations:</em></p><p>In post-marketing experience, there have been rare cases of osteoporosis including osteoporotic fractures reported in patients taking DEPO PROVERA IM.</p><p>Gynecology &ndash; Intramuscular (IM) Formulation</p><table border="1" cellspacing="0" cellpadding="0" style="width:103%"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Drug Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reaction, anaphylactoid reaction, angioedema, drug hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression, insomnia, nervousness</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness, headache, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism and thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Jaundice, jaundice cholestatic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia, hirsutism, acne, lipodystrophy acquired*,<strong> </strong>urticaria, pruritus, rash</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Dysfunctional uterine bleeding (irregular, increase, decrease, spotting), galactorrhoea, amenorrhoea, cervical discharge, uterine cervical erosion, breast pain, breast tenderness</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; Oedema, fluid retention, pyrexia, fatigue, injection-site reaction<sup>*</sup>, injection site persistent atrophy/indentation/dimpling<sup>*</sup>, injection site nodule/lump*, injection site pain/tenderness*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigations</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Glucose tolerance decreased, weight increased, weight decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* ADR identified post-marketing</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Oncology [Appendix A, Appendix B]</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:105%"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Drug Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, anaphylactoid reaction, angioedema, drug hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Corticoid-like effects, prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutritional disorders</p></td><td style="vertical-align:top"><p>Diabetes mellitus exacerbated, hypercalcaemia, weight fluctuation, increased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression, confusion, nervousness, insomnia, euphoria, changes in libido</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Cerebral infarction, headache, dizziness, loss of concentration, somnolence, adrenergic-like effects, tremors</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Retinal embolism and thrombosis, cataract diabetic, visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Cardiac failure congestive, myocardial infarction,&nbsp; tachycardia, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism and thrombosis, thrombophlebitis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting, diarrhoea, constipation, nausea, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia, acne, hirsutism, lipodystrophy acquired<sup>*</sup>, urticaria, pruritus, rash, hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and</p><p>connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary system disorders</p></td><td style="vertical-align:top"><p>Glycosuria</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting), amenorrhoea, uterine cervical erosions, cervical discharge, galactorrhoea, breast pain, erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Oedema/fluid retention, malaise, pyrexia, fatigue, injection-site reaction<sup>*</sup>, injection site persistent atrophy/indentation/dimpling<sup>*</sup>, injection site nodule/lump<sup>*</sup>, injection site pain/tenderness<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Glucose tolerance decreased, blood pressure increased, liver function test abnormal, white blood cell count increased, platelet count increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* ADR identified post-marketing</p></td></tr></tbody></table><p><sub>&nbsp;</sub></p><p><strong>Appendix A: ADRs and numeric frequencies listed in order of decreasing frequency within each SOC.</strong></p><p><strong>CONTRACEPTION (IM): ADRs and numeric frequencies listed in order of decreasing frequency within each SOC :</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>ADR term</p><p>(MedDRA 18.0</p><p>(when applicable))</p></td><td style="vertical-align:top"><p>Frequency n/N (%)</p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>0.36</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>10.83</p></td></tr><tr><td style="vertical-align:top"><p>Libido decreased</p></td><td style="vertical-align:top"><p>5.45</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>1.48</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>0.90</p></td></tr><tr><td style="vertical-align:top"><p>Anorgasmia</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>16.45</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>5.62</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>0.48</p></td></tr><tr><td style="vertical-align:top"><p>Seizure</p></td><td style="vertical-align:top"><p>0.12</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>0.95</p></td></tr><tr><td style="vertical-align:top"><p>(HLGT) Embolism and thrombosis</p></td><td style="vertical-align:top"><p>0.09</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain, Abdominal discomfort</p></td><td style="vertical-align:top"><p>11.24</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>3.31</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distention</p></td><td style="vertical-align:top"><p>2.31</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Liver disorder</p></td><td style="vertical-align:top"><p>0.24</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>1.19</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>1.12</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>1.10</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>0.52</p></td></tr><tr><td style="vertical-align:top"><p>Hirsutism</p></td><td style="vertical-align:top"><p>0.24</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>0.21</p></td></tr><tr><td style="vertical-align:top"><p>Lipodystrophy acquired*</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>2.21</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Vaginal discharge</p></td><td style="vertical-align:top"><p>2.93</p></td></tr><tr><td style="vertical-align:top"><p>Breast tenderness</p></td><td style="vertical-align:top"><p>2.76</p></td></tr><tr><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting)</p></td><td style="vertical-align:top"><p>0.57</p></td></tr><tr><td style="vertical-align:top"><p>Galactorrhoea</p></td><td style="vertical-align:top"><p>0.52</p></td></tr><tr><td style="vertical-align:top"><p>Pelvic pain</p></td><td style="vertical-align:top"><p>0.14</p></td></tr><tr><td style="vertical-align:top"><p>Breast pain</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Amenorrhoea</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Vaginitis</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>4.24</p></td></tr><tr><td style="vertical-align:top"><p>Fluid retention</p></td><td style="vertical-align:top"><p>2.17</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction*</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Injection site persistent atrophy/indentation/dimpling*</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Injection site nodule/lump*</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain/tenderness*</p></td><td style="vertical-align:top"><p>0.05</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>0.05</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>69</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>Bone density decreased</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Glucose tolerance decreased</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*ADR identified post-marketing</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>GYNECOLOGY (All Formulations Except For SC Formulation) - ADRs and numeric frequencies listed in order of decreasing frequency within each SOC :</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>ADR PT in MedDRA Version 18.0</p><p>(when applicable)</p></td><td style="vertical-align:top"><p>Frequency</p><p>n/N (%)</p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>2.35</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Prolonged anovulation<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>3.02</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>1.68</p></td></tr><tr><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>1.68</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>12.08</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>2.35</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>(HLGT) Embolism and thrombosis<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>10.40</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Jaundice<sup>&dagger;</sup>, Jaundice cholestatic<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>4.70</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>2.01</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>2.01</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>1.01</p></td></tr><tr><td style="vertical-align:top"><p>Hirsutism</p></td><td style="vertical-align:top"><p>0.34</p></td></tr><tr><td style="vertical-align:top"><p>Lipodystrophy acquired*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting)</p></td><td style="vertical-align:top"><p>17.79</p></td></tr><tr><td style="vertical-align:top"><p>Breast pain</p></td><td style="vertical-align:top"><p>3.69</p></td></tr><tr><td style="vertical-align:top"><p>Breast tenderness</p></td><td style="vertical-align:top"><p>2.35</p></td></tr><tr><td style="vertical-align:top"><p>Cervical discharge</p></td><td style="vertical-align:top"><p>1.01</p></td></tr><tr><td style="vertical-align:top"><p>Galactorrhoea</p></td><td style="vertical-align:top"><p>0.67</p></td></tr><tr><td style="vertical-align:top"><p>Amenorrhoea<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Uterine cervical erosion<sup>&dagger; </sup>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>3.69</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>2.68</p></td></tr><tr><td style="vertical-align:top"><p>Injection site persistent atrophy/indentation/dimpling*</p></td><td style="vertical-align:top"><p>1.37</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>1.34</p></td></tr><tr><td style="vertical-align:top"><p>Injection site nodule/lump*</p></td><td style="vertical-align:top"><p>0.69</p></td></tr><tr><td style="vertical-align:top"><p>Oedema, fluid retention</p></td><td style="vertical-align:top"><p>0.67</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain/tenderness*</p></td><td style="vertical-align:top"><p>0.34</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>2.01</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Glucose tolerance decreased<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*ADR identified post-marketing</p><p><sup>&dagger; </sup>ADR not reported in the dataset</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>ONCOLOGY- ADRs and numeric frequencies listed in order of decreasing frequency within each SOC :</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>ADR term in MedDRA 17.0</p><p><em>(when applicable)</em></p></td><td style="vertical-align:top"><p>Incidence</p><p>n/N (%)</p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>0.22</p></td></tr><tr><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Corticoid-like effects</p></td><td style="vertical-align:top"><p>0.97</p></td></tr><tr><td style="vertical-align:top"><p>Prolonged anovulation<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutritional disorders</p></td><td style="vertical-align:top"><p>Weight fluctuation</p></td><td style="vertical-align:top"><p>2.46</p></td></tr><tr><td style="vertical-align:top"><p>Increased appetite</p></td><td style="vertical-align:top"><p>1.19</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>0.22</p></td></tr><tr><td style="vertical-align:top"><p>Diabetes mellitus exacerbated</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>1.65</p></td></tr><tr><td style="vertical-align:top"><p>Euphoria</p></td><td style="vertical-align:top"><p>0.37</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>0.22</p></td></tr><tr><td style="vertical-align:top"><p>Changes in libido</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Confusion<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Tremors</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>1.35</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Cerebral infarction</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Loss of concentration<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Adrenergic-like effects<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual iDepo Proverairment<sup>&dagger; </sup>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Cataract diabetic<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Retinal embolism and thrombosis <sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Cardiac failure congestive</p></td><td style="vertical-align:top"><p>0.45</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Embolism and thrombosis</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.94</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>1.35</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1.12</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>0.52</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>2.31</p></td></tr><tr><td style="vertical-align:top"><p>Hirsutism</p></td><td style="vertical-align:top"><p>0.45</p></td></tr><tr><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Lipodystrophy acquired*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary system disorders</p></td><td style="vertical-align:top"><p>Glycosuria<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>1.51</p></td></tr><tr><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting)</p></td><td style="vertical-align:top"><p>0.69</p></td></tr><tr><td style="vertical-align:top"><p>Breast pain</p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td style="vertical-align:top"><p>Amenorrhoea<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Uterine cervical erosions<sup>&dagger; </sup>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Galactorrhoea<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Cervical discharge<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>4.18</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site reaction</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Oedema/fluid retention</p></td><td style="vertical-align:top"><p>1.72</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain/tenderness*</p></td><td style="vertical-align:top"><p>0.08%</p></td></tr><tr><td style="vertical-align:top"><p>Injection site persistent atrophy/indentation/dimpling*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Injection site nodule/lump*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>0.45</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Glucose tolerance decreased</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Blood pressure increased</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>Liver function test abnormal<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>White blood cell count increased<sup>&dagger; </sup>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count increased<sup>&dagger; </sup>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*ADR identified post-marketing</p><p><sup>&dagger; </sup>ADR not reported in the dataset</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Appendix B: ADRs by SOC and CIOMS frequency category listed in order of decreasing medical seriousness or clinical importance within each frequency category and SOC.</strong></p><p><strong>&nbsp;CONTRACEPTION (IM): </strong></p><p>The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 4200 women who received DEPO PROVERA for contraception for up to 7 years. <strong>&nbsp;</strong>&nbsp;Those most frequently (&gt;5%) reported adverse drug reactions were weight increased (69%), weight decreased (25%), headache (16%), nervousness (11%), abdominal pain or discomfort (11%), dizziness (6%), and decrease in libido (6%).</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common &ge; 1/10</p></td><td style="vertical-align:top"><p>Common &ge; 1/100 to &lt;&nbsp;1/10</p></td><td style="vertical-align:top"><p>Uncommon&ge; 1/1000 to &lt;&nbsp;1/100</p></td><td style="vertical-align:top"><p>Rare &ge; 1/10,000 to &lt; 1/1000</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, Anaphylactoid reaction, Angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>Depression, Libido decreased</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anorgasmia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Seizure, Somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>Embolism and thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Abdominal pain, Abdominal discomfort,</p></td><td style="vertical-align:top"><p>Nausea, Abdominal distension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver disorder</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, Acne, Rash</p></td><td style="vertical-align:top"><p>Hirsutism, Urticaria, Pruritus</p></td><td style="vertical-align:top"><p>Lipodystrophy acquired*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia, Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vaginal discharge, Breast tenderness</p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting), Galactorrhoea, Pelvic pain</p></td><td style="vertical-align:top"><p>Vaginitis, Amenorrhoea, Breast pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fluid retention, Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, Fatigue, Injection site reaction*, Injection site persistent atrophy/indentation/dimpling*, Injection site nodule/lump*,&nbsp; Injection site pain/tenderness*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Weight increased, Weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bone density decreased, Glucose tolerance decreased</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*ADR identified post-marketing</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>GYNECOLOGY (All Formulations Except For SC Formulation):</strong></p><p>The table below provides a listing of adverse drug reactions with frequency based on all-causality data from Phase 3 clinical studies that evaluated efficacy and safety of DEPO PROVERA in gynecology. Those most frequently (&gt;5%) reported adverse drug reactions were dysfunctional uterine bleeding (19%), headache (12%) and nausea (10%) <strong>:</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common &ge; 1/10</p></td><td style="vertical-align:top"><p>Common &ge; 1/100 to &lt;&nbsp;1/10</p></td><td style="vertical-align:top"><p>Uncommon&ge; 1/1000 to &lt;&nbsp;1/100</p></td><td style="vertical-align:top"><p>Not known (cannot be estimated from available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, Anaphylactoid reaction, Angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression, Insomnia, Nervousness</p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td><td style="vertical-align:top"><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td><td style="vertical-align:top"><p>Embolism and thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice, Jaundice cholestatic</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, Acne, Urticaria, Pruritus,</p></td><td style="vertical-align:top"><p>Hirsutism</p></td><td style="vertical-align:top"><p>Lipodystrophy acquired*, Rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting)</p></td><td style="vertical-align:top"><p>Cervical discharge,&nbsp; Breast pain, Breast tenderness</p></td><td style="vertical-align:top"><p>Galactorrhoea</p></td><td style="vertical-align:top"><p>Amenorrhoea, Uterine cervical erosion</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, Fatigue, Injection site reaction*, Injection site persistent atrophy/indentation/dimpling*</p></td><td style="vertical-align:top"><p>Oedema, Fluid retention, Injection site nodule/lump*, Injection site pain/tenderness*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p><em><u>&nbsp;</u></em></p></td><td style="vertical-align:top"><p>Glucose tolerance decreased, Weight decreased</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*ADR identified post-marketing</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>ONCOLOGY: </strong></p><p>The table below provides a listing of adverse drug reactions with frequency based on all-causality data from 1337 patients who received DEPO PROVERA in 4 pivotal studies that evaluated efficacy and safety of DEPO PROVERA for oncology indications .</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:697px"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common &ge;1/10</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100 to &lt;&nbsp;1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge; 1/1000 to &lt;&nbsp;1/100</p></td><td style="vertical-align:top"><p>Rare &ge; 1/10,000 to &lt; 1/1000</p></td><td style="vertical-align:top"><p>Frequency Not Known (cannot be estimated from the available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<s> </s></p></td><td style="vertical-align:top"><p>Anaphylactic reaction, Anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Corticoid-like effects</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prolonged anovulation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutritional disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight fluctuation, Increased appetite</p></td><td style="vertical-align:top"><p>Diabetes mellitus exacerbated,</p><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Depression, Euphoria, Changes in libido</p></td><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache, Dizziness, Tremors</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Cerebral infarction, Somnolence</p></td><td style="vertical-align:top"><p>Loss of concentration, Adrenergic-like effects</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Retinal embolism and thrombosis, Cataract diabetic, Visual iDepo Proverairment</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac failure congestive</p></td><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>Embolism and thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting, Constipation, Nausea</p></td><td style="vertical-align:top"><p>Diarrhoea,<br />Dry mouth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Acne,</p><p>Hirsutism</p></td><td style="vertical-align:top"><p>Alopecia,</p><p>Rash</p></td><td style="vertical-align:top"><p>Lipodystrophy acquired*, Urticaria,</p><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glycosuria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Dysfunctional uterine bleeding (irregular, increase, decrease, spotting),</p><p>Breast pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amenorrhoea, Uterine cervical erosions,</p><p>&nbsp;Cervical discharge, Galactorrhoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema /fluid retention, Fatigue, Injection site reaction*</p></td><td style="vertical-align:top"><p>Injection site pain/tenderness*</p></td><td style="vertical-align:top"><p>Malaise,</p><p>&nbsp;Pyrexia</p></td><td style="vertical-align:top"><p>Injection site persistent atrophy/indentation/dimpling*, Injection site nodule/lump*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Glucose tolerance decreased,</p><p>Blood pressure increased</p></td><td style="vertical-align:top"><p>Liver function test abnormal,</p><p>&nbsp;White blood cell count increased, Platelet count increased</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>*ADR identified post-marketing</p></td></tr></tbody></table><p><sub>&nbsp;</sub></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p><strong>To report side effects: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose treatment is symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medroxyprogesterone acetate (17a‑hydroxy‑6a‑methylprogesterone acetate) is a derivative of progesterone.</p><p><em>Mechanism of Action</em></p><p>DEPO PROVERA is a synthetic progestin (structurally related to the endogenous hormone progesterone) which has been demonstrated to possess several pharmacologic actions on the endocrine system:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibition of pituitary gonadotropins (FSH and LH);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of ACTH and hydrocortisone blood levels;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of circulating testosterone;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of circulating estrogen levels (as the result of both FSH inhibition and enzymatic induction of hepatic reductase, resulting in increased clearance of testosterone and consequent decreased conversion of androgens to estrogens).</p><p>All of these actions result in a number of pharmacological effects, as described below.</p><p><em>Contraception</em></p><p>DEPO PROVERA, when administered parenterally at the recommended dose to women, inhibits the secretion of gonadotropins which, in turn, prevents follicular maturation and ovulation and causes thickening of cervical mucus which inhibits sperm entry into the uterus.</p><p><em>Gynecology</em></p><p>Medroxyprogesterone acetate (DEPO PROVERA), administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered DEPO PROVERA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses.</p><p><em>Endometriosis</em></p><p>Suppression of serum estradiol concentrations and a possible direct action of DMPA SC on the lesions of endometriosis are likely to be responsible for the therapeutic effect on endometriosis-associated pain.</p><p><em>Oncology</em></p><p>DEPO PROVERA demonstrates antitumor activity. When DEPO PROVERA is given to patients at high doses (either by the oral route or by IM injection) it is effective in the palliative treatment of hormone-responsive malignant neoplasms.</p><p><em>Clinical Studies</em></p><p><u>BMD Studies</u></p><p>BMD Changes in Adult Women</p><p>In a non-randomized controlled clinical study comparing adult women using DEPO PROVERA contraceptive injection (150 mg IM) for up to 5&nbsp;years to women who elected to use no hormonal contraception, 42 DEPO PROVERA users completed 5 years of treatment and provided at least 1 follow-up BMD measurement after stopping DEPO PROVERA. Among DEPO PROVERA users, BMD declined during the first 2 years of use, with little declines in subsequent years. Mean changes in lumbar spine BMD of -2.86%, -4.11%, -4.89%, -4.93% and -5.38% after 1, 2, 3, 4 and 5 years, respectively, were observed. Mean decreases in BMD of the total hip and femoral neck were similar. There were no significant changes in BMD in the control women over the same period of time.</p><p>BMD recovery post-treatment in adult women</p><p>In the same study population, there was partial recovery of BMD toward baseline values during the 2-year period after stopping use of DEPO PROVERA injection (150 mg IM)</p><p>After 5 years of treatment with DEPO PROVERA injection (150 mg IM), the mean % change in BMD from baseline was -5.4%, -5.2% and -6.1% at the spine, total hip and femoral neck, respectively, while untreated control women, over the same time interval, showed mean changes from baseline of +/- 0.5%&nbsp; or less at the same skeletal sites.&nbsp; Two years after stopping DEPO PROVERA injections, mean BMD had increased at all 3 skeletal sites but deficits remained: -3.1%, -1.3% and -5.4% at the spine, total hip and femoral neck, respectively. At the same time point, women in the control group showed mean changes from baseline BMD of 0.5%, 0.9% and -0.1% at the spine, total hip and femoral neck, respectively.</p><p>BMD Changes in Adolescent Females (12-18 years)</p><p>The effect of DEPO PROVERA injectable (150 mg IM) use on BMD for up to 240 weeks (4.6 years) was evaluated in an open-label non-comparative clinical study of 159 adolescent females (12-18 years) who elected to begin treatment with DEPO PROVERA; 114 of the 159 participants used DEPO PROVERA continuously (4 injections during each 60-week period) and had BMD measured at Week 60.&nbsp; BMD declined during the first 2 years of use with little change in subsequent years.&nbsp; After 60 weeks of DEPO PROVERA use, mean % BMD changes from baseline were -2.5%, -2.8% and -3.0% at the spine, total hip and femoral neck, respectively. A total of 73 subjects continued to use DEPO PROVERA through 120 weeks; mean % BMD changes from baseline were -2.7%, -5.4% and -5.3% at the spine, total hip and femoral neck, respectively. A total of 28 subjects continued to use DEPO PROVERA through 240 weeks; mean % BMD changes from baseline were -2.1%, -6.4% and -5.4% at the spine, total hip and femoral neck, respectively.</p><p><strong>BMD recovery post-treatment in adolescents </strong></p><p>In the same study, 98 adolescent participants received at least 1 DEPO PROVERA injection and provided at least 1 follow-up BMD measurement after stopping DEPO PROVERA use, with DEPO PROVERA treatment for up to 240 weeks (equivalent to 20 DEPO PROVERA injections) and post-treatment follow-up extending for up to 240 weeks after the final DEPO PROVERA injection<strong>. </strong>The median number of injections received during the treatment phase was 9. At the time of the final DEPO PROVERA injection, BMD % changes from baseline were -2.7%, -4.1% and -3.9% at the spine, total hip and femoral neck, respectively.&nbsp; Over time these mean BMD deficits fully recovered after DEPO PROVERA was discontinued.&nbsp; Full recovery required 1.2 years at the lumbar spine, 4.6 years at the total hip and 4.6 years at the femoral neck.&nbsp; Longer duration of treatment and smoking were associated with slower recovery. See<strong>&nbsp;Section&nbsp;4.4.&nbsp;Special warnings and precautions for use - <em>Additional Warnings and Precautions for Specific Use or Formulation, </em></strong><u>Contraception/Endometriosis - Injectable Formulations:</u><strong> </strong>Loss of Bone Mineral Density (BMD).</p><p><strong>Relationship of fracture incidence to use of DEPO PROVERA injectable (150 mg IM) or non-use by women of reproductive age </strong></p><p>A retrospective cohort study to assess the association between DEPO PROVERA injection and the incidence of bone fractures was conducted in 312,395 female contraceptive users in the UK. The incidence rates of fracture were compared before and after DEPO PROVERA use started and also between DEPO PROVERA users and women who used other contraceptives but had no recorded use of DEPO PROVERA. Among women using DEPO PROVERA, use of DEPO PROVERA was not associated with an increase in fracture risk (incident rate ratio = 1.01, 95% CI 0.92-1.11, comparing the study follow-up period with up to 2 years of observation prior to DEPO PROVERA use).&nbsp; However, DEPO PROVERA users did have more fractures than non-users not only after first contraceptive use (IRR = 1.23, 95% CI 1.16-1.30), but also before first contraceptive use (IRR = 1.28, 95% CI 1.07-1.53).</p><p>In addition, fractures at the specific bone sites characteristic of osteoporotic fragility fractures (spine, hip, pelvis) were not more frequent among DEPO PROVERA users compared to non-users (IRR = 0.95, 95% CI 0.74-1.23), nor was there any evidence that longer use of DEPO PROVERA (2 years or more) confers greater risk for fracture compared to less than 2 years of use.</p><p>These data demonstrate that DEPO PROVERA users have an inherently different fracture risk profile to non-users for reasons not related to DEPO PROVERA use.</p><p>Maximum follow-up in this study was 15 years, therefore, possible effects of DEPO PROVERA that might extend beyond 15 years of follow-up cannot be determined.</p><p><u>Endometriosis Studies</u></p><p>The efficacy of DEPO PROVERA SC in the reduction of endometriosis-associated pain in women with the signs and symptoms of endometriosis was demonstrated in two active comparator -controlled studies.&nbsp; Each study assessed reduction in endometriosis-associated pain over 6 months of treatment and recurrence of symptoms for 12 months post treatment.&nbsp; Subjects treated with DEPO PROVERA SC for 6 months received a 104 mg dose every 3 months (2&nbsp;injections), while women treated with leuprolide<strong> </strong>microspheres for 6 months received a dose of 11.25 mg every 3&nbsp;months (2 injections) or 3.75 mg every month (6 injections).&nbsp; Study&nbsp;268 was conducted in the USA and Canada and enrolled 274 subjects (136 on DEPO PROVERA SC and 138 on leuprolide).&nbsp; Study 270 was conducted in South America, Europe and Asia, and enrolled 299 subjects (153 on DEPO PROVERA SC and 146 on leuprolide).</p><p>Reduction in pain was evaluated using a modified Biberoglu and Behrman scale that consisted of three patient-reported symptoms (dysmenorrhoea, dyspareunia, and pelvic pain not related to menses) and two signs assessed during pelvic examination (pelvic tenderness and induration). For each category, a favorable response was defined as improvement of at least 1 unit (severity was assessed on a scale of 0 to 3) relative to baseline score (Figure 1).</p><p>&nbsp;</p><p>Favorable Response = reduction in severity of symptom or sign of <u>&gt;</u>1 point on a scale of 0 to 3, as compared to baseline.</p><p>Additionally, scores from each of the five categories were combined, with the total (composite score) considered a global measurement of overall disease improvement. For subjects with baseline scores for each of the 5 categories, a mean decrease of 4 points relative to baseline was considered a clinically meaningful improvement. Across both studies, for both treatment groups, the mean changes in the composite score met the protocol-defined criterion for improvement.</p><p>In the clinical trials, treatment with DEPO PROVERA SC was limited to six months. Data on the persistence of benefit with longer treatment are not available.</p><p>Subjects recorded daily the occurrence and severity of hot flushes. Of the DEPO PROVERA SC users, 28.6% reported experiencing moderate or severe hot flushes at baseline, 36.2% at Month 3, and 26.7% at Month 6. Of the leuprolide users, 32.8% reported experiencing moderate or severe hot flushes at baseline, 74.2% at Month 3, and 68.5% at Month 6.</p><p><u>Women&rsquo;s Health Initiative Study</u></p><p>The WHI CEE (0.625mg)/DEPO PROVERA (2.5mg) trial<strong> </strong>&nbsp;enrolled 16,608 postmenopausal women aged 50-79 years with intact uteri at baseline, to assess the risks and benefits of the combined therapy compared with placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome studied. The study was stopped early after an average follow-up of 5.2 years (planned duration 8.5 years) because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the &ldquo;global index&rdquo; (<strong>see Section 4.4. Special warnings and precautions for use</strong>, <u>Breast Cancer</u>).</p><p>The combination CEE/DEPO PROVERA therapy reported a significant decrease in osteoporotic (23%) and total (24%) fractures.</p><p><u>Million Women Study</u></p><p>The MWS <strong>&nbsp;</strong>was a prospective cohort study enrolling 1,084,110 women in the UK aged 50-64 years of whom 828,923 with defined time since menopause were included in the main analyses of risk of breast cancer in relation to HT. Overall, 50% of the study population had used HT at some point. Most current users of HT at baseline reported using preparations containing estrogen only (41%) or estrogen-progestin combinations (50%). The average duration of follow-up was 2.6 years for analyses of cancer incidence and 4.1 years for analyses of mortality (<strong>see Section</strong> <strong>4.4</strong> <strong>Special warnings and precautions for use,</strong> <u>Breast Cancer</u>).</p><p><u>Heart and Estrogen/progestin Replacement Studies </u></p><p>HERS &nbsp;and HERS II <strong>&nbsp;</strong>studies were two randomized, prospective secondary prevention trials on the long-term effects of oral continuous combined CEE/DEPO PROVERA (0.625 mg CEE plus 2.5mg DEPO PROVERA) regimen in postmenopausal women with CHD (<strong>see Section 4.4. Special warnings and precautions for use - </strong><u>Cardiovascular disorders</u>). 2, 763 postmenopausal women with a mean age of 66.7 years and with intact uteri were enrolled in this study. The average duration of follow-up was 4.1 years for HERS and 2.7 additional years (for a total of 6.8 years) for HERS II (<strong>see Section 4.4. Special warnings and precautions for use - </strong><u>Cardiovascular Disorders</u>).</p><p><u>Women&rsquo;s Health Initiative Memory Study </u></p><p>The WHIMS, a substudy of WHI, <strong>&nbsp;</strong>enrolled 4,532 predominantly healthy postmenopausal women age 65 to 79 years to evaluate the effects of CEE/DEPO PROVERA (0.625 mg CEE plus 2.5 mg DEPO PROVERA) or CEE-alone (0.625 mg) on the incidence of probable dementia compared with placebo. The average duration of follow-up was 4.05 years for the CEE/DEPO PROVERA (<strong>see Section 4.4. Special warnings and precautions for use - </strong><u>Dementia</u>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Subcutaneous formulation</em></p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>MPA absorption from the SC injection site to achieve therapeutic levels is relatively prompt. The mean T<sub>max </sub>attained approximately one week after injection. The peak MPA concentrations (C<sub>max)</sub> generally range from 0.5 to 3.0 ng/mL with a mean C<sub>max </sub>of 1.5&nbsp;ng/mL after a single SC injection.&nbsp;</p><p>Effect of Injection Site</p><p>DMPA subcutaneous was administered into the anterior thigh or the abdomen to evaluate effects on MPA concentration-time profile. MPA trough concentrations (C<sub>min;</sub> Day 91) were similar for the two injection locations, suggesting that injection site does not negatively affect the contraceptive efficacy.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding of MPA averages 86%. MPA binding occurs primarily to serum albumin; no binding of MPA occurs with Sex Hormone-Binding Globulin (SHBG).</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p>MPA is extensively metabolized in the liver.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>Residual MPA concentrations at the end of the dosing interval (3 months) of DMPA sucutaneous are generally below 0.5 ng/mL, consistent with its apparent terminal half-life of ~40 days after SC administration. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only small amounts excreted as sulfates.</p><p><u>&nbsp;</u></p><p><strong>Special Populations:</strong></p><p><u>&nbsp;</u></p><p><u>Race</u></p><p>There were no apparent differences in the pharmacokinetics and/or dynamics of MPA after SC administration of DMPA subcutaneous among women of all ethnic backgrounds studied. The pharmacokinetics/dynamics of DMPA has been evaluated in Asian women in a separate study.</p><p><u>&nbsp;</u></p><p><u>Effect of Body Weight</u></p><p>No dosage adjustment of DMPA subcutaneous is necessary based on body weight. The effect of body weight on the pharmacokinetics of MPA was assessed in a subset of women (n&nbsp;= 42, body mass index [BMI] ranged from 18.2 to 46.0&nbsp;kg/m<sup>2</sup>). The AUC<sub>0-91</sub> values for MPA were 68.5, 74.8, and 61.8 ng day/mL in women with BMI categories of &pound;25 kg/m<sup>2</sup>, &gt;25 kg/m<sup>2 </sup>to &le;30 kg/m<sup>2</sup>, and &gt;30 kg/m<sup>2</sup>,<sup> </sup>respectively. The mean MPA Cmax was 1.65 ng/mL in women with BMI &pound;25&nbsp;kg/m<sup>2</sup>, 1.76 ng/mL in women with BMI &gt;25 kg/m<sup>2</sup> to &le;30 kg/m<sup>2</sup>, and 1.40&nbsp;ng/mL in women with BMI &gt;30&nbsp;kg/m<sup>2</sup>, respectively. The range of MPA trough (C<sub>min</sub>) concentrations and the half-lives were comparable for the 3 BMI groups.</p><p><em>&nbsp;</em></p><p><em>Intramuscular formulations</em></p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Following intramuscular administration, DEPO-PROVERA is slowly released, resulting in low, but persistent levels in the circulation. Immediately after intramuscular injection of 150mg/ml DEPO-PROVERA, plasma levels were 1.7 &plusmn; 0.3 nmol/L. Two weeks later, levels were 6.8 &plusmn; 0.8 nmol/L.&nbsp; Mean time to peak is approximately 4 to 20 days following an intramuscular dose. Serum medroxyprogesterone acetate levels gradually decline and remain relatively constant at about 1 ng/mL for 2‑3 months. Circulating levels can be detected for as long as 7 to 9&nbsp;months following an intra&shy;muscular injection.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>DEPO-PROVERA is approximately 90 to 95 % protein bound. Volume of distribution is reported as 20 <u>+</u> 3 liters. Medroxyprogesterone acetate crosses the blood‑brain‑barrier, and the placental barrier (<strong>see Section 4.6. Pregnancy and lactation</strong>). Low levels of medroxyprogesterone acetate have been detected in breast milk of lactating women (<strong>see Section 4.6 &ndash; Pregnancy and lactation</strong>) administered 150 mg of medroxyprogesterone acetate by the IM route.</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p>DEPO-PROVERA is metabolized in the liver.&nbsp;</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The elimination half‑life following single intramuscular injection is about 6&nbsp;weeks.&nbsp; Medroxyprogesterone acetate is primarily excreted in the feces, via biliary secretion. Approximately 30% of an intramuscular dose is secreted in the urine after 4 days.</p><p><em>&nbsp;</em></p><p><em>Oral formulations</em></p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Oral medroxyprogesterone (MPA) is rapidly absorbed with maximum concentration obtained between 2 to 4 hours. The half-life of oral MPA is approximately 17&nbsp;hours. It is 90% protein bound, and is mainly excreted in the urine.&nbsp;</p><p>Administration with food increases the bioavailability of MPA. A 10 mg dose of oral MPA, taken immediately before or after a meal, increased average MPA C<sub>max</sub> (51 and 77%, respectively) and average AUC (18 and 33%, respectively). The half-life of MPA was not changed with food.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>MPA is approximately 90% protein bound, primarily to albumin; no MPA binding occurs with sex hormone-binding globulin. The unbound MPA modulates pharmacologic responses.</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p>Following oral dosing, MPA is extensively metabolized in the liver via ring A and/or side-chain hydroxylation, with subsequent conjugation and elimination in the urine. At least 16&nbsp;MPA metabolites have been identified. In a study designed to measure the metabolism of medroxyprogesterone acetate (MPA), the results suggest that human cytochrome P450 3A4 is primarily involved in the overall metabolism of MPA in human liver microsomes.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. Mean percent dose excreted in the 24-hour urine of patients with fatty liver as intact MPA after a 10 mg or 100 mg dose was 7.3% and 6.4%, respectively. Elimination half-life of oral MPA is 12 to 17 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Carcinogenesis, Mutagenesis, Impairment of Fertility</em></strong></p><p>Long-term intramuscular administration of medroxyprogesterone acetate (DEPO-PROVERA) has been shown to produce mammary tumors in beagle dogs. There was no evidence of a carcinogenic effect associated with the oral administration of oral DEPO-PROVERA to rats and mice. Medroxyprogesterone acetate was not mutagenic in a battery of <em>in vitro </em>or <em>in vivo </em>genetic toxicity assays. Medroxyprogesterone acetate at high doses is an antifertility drug and high doses would be expected to impair fertility until the cessation of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Macrogol 3350, polysorbate 80, sodium chloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, water for injections, hydrochloric acid and/or sodium hydroxide for the pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 Months.

Do not use DEPO-PROVERA after the expiry date which is stated on the carton / Vial label after EXP:. The expiry date refers to the last day of that month.
The expiry date is mentioned on the package after the letters EXP. (EXP. = expiry date).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Do not refrigerate or freeze.</p><p>Store vial upright.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sterile aqueous suspension for intramuscular injection.</p><p>&nbsp;</p><p><u>Presentations</u>:</p><p>DEPO-PROVERA 150 mg suspension for injection:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.3 ml vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Vial: shake well just before use in order to obtain homogeneous suspension.</p><p>&nbsp;</p><p>Pre-filled syringe: shake well just before use in order to obtain homogeneous suspension.</p><p>1. Remove the protective cap.</p><p>2. Fit the needle to the syringe.</p><p>3. Remove the protective sheath from the needle.</p><p>&nbsp;</p><p>The syringe is ready to use.</p><p>&nbsp;</p><p>&nbsp;</p><p>After use, the syringe cannot be reused and must be discarded.</p><p><strong>&nbsp;</strong></p><p><strong>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER:
Pfizer S.A., 17 Boulevard de la Plaine, 1050 Brussels, Belgium. 

Manufactured By:
Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>